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ABSTRACT 
 
 
The objective of the study was to develop a controlled release dosage form of 
insulin, which can provide basal concentrations of insulin in diabetic rats for 1 to 2 weeks 
after a single subcutaneous injection. 
 
A biodegradable injectable drug delivery gel was prepared by dissolving a 
biodegradable polymer, polylactic-co-glycolic acid (PLGA), in biocompatible 
plasticizer(s), triethyl citrate (TEC) and/or acetyl triethyl citrate (ATEC). Insulin was 
then loaded into the blank gel to form an insulin suspension in the polymer solution. 
After the insulin-loaded gel was injected subcutaneously, the plasticizer(s) dissolved in 
the aqueous media and were gradually taken away from the gel. The polymer precipitated 
after the plasticizer(s) were extracted by the aqueous medium and a solid depot of insulin 
was formed. The insulin was released slowly from the depot by a combination of drug 
diffusion and erosion of the polymer. 
 
In the first part of this study, the effect of different water-soluble and water-
insoluble zinc salts on blood glucose lowering effect of insulin in type-2 diabetic ZDF 
rats was investigated. Insulin formulations containing varying concentrations of different 
water-soluble and water-insoluble zinc salts were prepared and injected subcutaneously 
in type-2 ZDF rats and blood glucose concentration lowering effect was studied. Insulin 
in presence of water-soluble salts of zinc could suppress blood glucose concentrations in 
ZDF rats for up to 16 hours. 
 
Insulin was loaded into different gel formulations (5% PLGA (i.v. 0.09, acid end 
group), ATEC:TEC (3:1) and 4% insulin) and tested in vivo. However, these insulin-
loaded gel formulations only suppressed the blood glucose concentrations in the ZDF rats 
for 1 day after a single subcutaneous injection. In order to achieve longer control over the 
release of insulin from the gels, a water-soluble salt, zinc sulfate was incorporated in 
these insulin containing gels at different concentrations. A biodegradable injectable gel 
formulation prepared with zinc sulfate was able to maintain low blood glucose 
concentrations for up to 8 to 10 days following a single subcutaneous injection. 
 
In order to achieve better glucose control after the release of insulin from the gels, 
insulin glargine particles were purified from commercially available Lantus® formulation. 
The freeze dried insulin glargine particles were then loaded into the blank gels and tested 
in vivo. The formulation prepared with 5% PLGA (i.v. 0.09, acid end group), ATEC:TEC 
(3:1) and 4% insulin glargine was able to suppress the blood glucose concentrations of 
the ZDF rats significantly for 10 days after a single subcutaneous injection. The 
concentration of insulin glargine was maintained between 260 ± 134.9 mIU/L and 188 ± 
55.9 mIU/L until day 10 after single subcutaneous injection. The addition of zinc sulfate 
to the formulations prepared with purified insulin glargine particles further slowed down 
the drop in blood glucose concentrations. 
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CHAPTER 1. INTRODUCTION 
 
 
1.1 Diabetes mellitus 
 
Diabetes mellitus is a chronic disorder. It may be defined as “a metabolic disorder 
of multiple etiologies characterized by chronic hyperglycemia with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, 
insulin action, or both” (1). 
 
Even though diabetes has been known to humans from early historical periods, it 
is only recently that the WHO (World Health Organization) has recognized it as first non-
infectious, worldwide epidemic (2). The cause of diabetes was unknown for centuries. 
Then in 1889, Joseph Von Mering and Oskar Minkowski demonstrated in dogs that the 
disease was associated with pancreas (3). In 1908, a German scientist, Georg Zuelzer 
prepared a crude extract from animal pancreas and unsuccessfully tried to treat human 
diabetic subjects (4). In 1921, one of the most phenomenal discoveries of medical history 
was done by Frederick Banting and Charles Best. They isolated an antidiabetic substance, 
which was later named as “isletin”, from dog pancreas and injected in two 
pancreatectomized, hyperglycemic dogs. The blood glucose concentrations of these 
‘isletin’ injected dogs reduced significantly. John Macleod and James Collip further 
purified the extract from pancreas and named ‘isletin’ as insulin. They successfully used 
insulin to treat a 14 year old diabetic boy (4). This historical treatment marked the 
beginning of the use of insulin in the treatment of diabetes. In 1923, Frederick Banting 
and John Macleod were awarded the Nobel Prize in physiology for their discovery of 
insulin (5). Later, Banting shared his Nobel Prize with Best, and soon after Macleod 
shared his Noble Prize with Collip (1). 
 
1.1.1 Type-1 diabetes 
 
It is a well established fact now that diabetes mellitus is not a single disease but a 
combination of different types of diseases. It is broadly categorized as diabetes type-1, 
diabetes type-2 and gestational diabetes (6). 
 
The diabetes type-1 is caused by deficiency of insulin, and has more common 
juvenile onset which is active in nature and requires insulin delivery for survival (6). The 
deficiency of insulin is caused by autoimmune destruction of beta cells in the pancreas. 
 
The type-1 diabetes may further be divided into two classes: type-1 A and type-1 
B. Type 1 A disease is due to autoimmune destruction of the beta cells in pancreas, thus 
reducing the biosynthesis of insulin. Antibodies against the beta cells antigen have been 
found in those subjects. Type-1 B disease is idiopathic, i.e. no beta cell antibodies are 
found in the subjects (6). 
 
1.1.1.1 Role of genetics toward susceptibility to type-1 diabetes. It is a well 
recognized fact that genetics plays an important role in type-1 diabetes. For example, the 
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concordance rate in monozygotic twins is much higher than the dizygotic twins (6-8). 
Further, some ethnic groups are more susceptible to type-1 diabetes than others. The first 
degree relative of type-1 subjects are 15 fold more prone to suffer from type-1 diabetes 
(6, 9). Davis et al. reported that the major genetic determinant of susceptibility to type-1 
diabetes is HLA region of chromosome 6 (10). The insulin gene region on chromosome 
11 and other confounded genes have also been implicated. 
 
1.1.1.2 Environmental factors. The concordance rate for the development of type-
1 diabetes in monozygotic twins is not 100%. Further, there are reports suggesting 
seasonal peak in the case of type-1 diabetes detection (9). This indicates of some 
environmental factors or the possible interaction of gene and environmental factors are 
playing a role in the development of type -1 diabetes (9). One of the Scandinavian studies 
indicated a correlation between an increase in diabetes incidences and the decline in 
breast feeding. The study suggested that tolerance to the common antigen might not be 
developed if children were exposed to cow milk protein in their early ages (11). Certain 
virus infection, for example Poliovirus, entero virus, and echovirus, have been suggested 
as the possible reasons for the autoimmune responses against the beta cells of pancreas 
(12). Exposer to virus infection during early childhood or pregnancy have been 
associated with type-1 diabetes as well (13-16). 
 
1.1.1.3 Prevention of type-1 diabetes. There are various prevention trial studies 
going on around the world. The trials may be primary, secondary or tertiary. The aim of 
these trials is slowing the progression of type-1 diabetes (6). The primary prevention 
trials are before development of autoimmunity and are conducted in patients who are 
more prone to diabetes due to their genetic make up. Secondary preventive trials are 
those which are conducted in subjects showing signs of autoimmunity, but are not 
diabetic yet. Cyclosporine, an immunosuppressant, insulin and nicotinamide, a vitamin 
B3 derivative, alone or in combinations have been injected in these subjects, and 
development of diabetes has been studied. Some of these trials have been effective, but 
only for an year (17). 
 
1.1.2 Type-2 diabetes 
 
Type-2 diabetes or non insulin dependent diabetes mellitus is also known as 
maturity onset diabetes mellitus (18). Type-2 diabetes is a complex disorder that might be 
due to one or more than one gene, environmental factors or interaction of both (18, 19). 
In type-2 diabetes, there may be no loss or some loss of beta cells, and insulin 
concentrations in the blood may be high, normal or low. Type-2 diabetes subjects have a 
high degree of genetic predisposition, and the onset is generally late (18, 20). Type-2 
diabetes, in most cases has a slow progression. The interaction between genetic and 
environmental factors affects the pathogenesis of type-2 diabetes (18). Genetically 
predisposed subjects follow a particular trend in the progression of diabetes. The normal 
subjects develop insulin resistance, hyperinsuleneimia, glucose desensitization, and 
insulin secretion defects leading to impaired glucose tolerance followed by 
hyperglycemia leading to type-2 diabetes (18, 21). The type-2 diabetes may also be due 
to various reasons such as, malfunction of gluco-receptor on the surface of cells, so that 
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they start responding to only high glucose concentration in the blood. There may be down 
regulation of insulin receptors leading to reduction in frequency of these receptors. The 
presence of hyperglycemic hormones like glucagon and physical state like obesity may 
also result in insulin deficiency leading to type-2 diabetes. 
 
Glucose concentrations in the blood are controlled by three mechanisms; hepatic 
glucose production, peripheral tissue glucose uptake (glucose uptake by muscles 
adipocytes and hepatic cells) and insulin secretion by beta cells (18, 22). There exists a 
critical balance between these three mechanisms. Factors affecting any of these 
biochemical processes may lead to type-2 diabetes. An increase in hepatic glucose 
production by increasing glycogenolysis or gluconeogenesis increases glucose 
concentrations (23). This may be due to a decrease in the effectiveness of insulin or low 
insulin concentrations, or an increase in the glucagon concentrations. A combination of 
the above reasons may also contribute to the increased blood glucose dumping by the 
liver, thus leading to diabetes type-2 (24-27). 
 
Genetic components have a strong influence in the development of type-2 
diabetes (18). It has been well recognized that type-2 diabetes is multi-genetic in nature. 
Different candidate genes that may effect the development and progression of type-2 
diabetes have been studied. These genes have been further divided into two categories. 
The first category contains candidate genes for insulin secretary defects, while the second 
category has candidate gene for insulin resistance (18). Although various candidate genes 
affecting the insulin secretion and resistance have been studied, no single gene mutation 
that is responsible for the cause and progression of type-2 diabetes has been identified 
(18). 
 
 
1.2 Insulin 
 
Insulin is a metabolic hormone synthesized, stored, and secreted from beta cells of 
pancreas. In an important landmark, Abel et al. successfully crystallized insulin in 1927 
(28). Scott and Fisher in 1935 studied the role of zinc in insulin crystallization (29-31). 
The crystallization techniques helped in improving the yields and purity of insulin. In 
1936, Hagedon came out with insulin protamine suspensions, which increased the 
duration of antidiabetic effect of insulin and lowered the hypoglycemic reactions (32). 
However, the protamine insulin was not stable and had a tendency to stick to the walls of 
the vials, thus reducing its potency (33, 34). This problem was solved by Scott and Fisher 
by adding zinc salts to the insulin protamine formulation and forming protamine zinc 
insulin. This not only stabilized the insulin protamine formulation for more than six 
months, but also prolonged the absorption time of insulin (33, 34). In 1951, Hallas-
Moller et al. came out with an idea of Lente insulins. Semilente insulin was a suspension 
of amorphous insulin and zinc particles, and had a longer action than normal insulin. 
Ultralente was a crystalline modification (crystallized in acetate buffer) with a longer 
action similar to protamine zinc insulin. Lente insulin formulation contained a mixture of 
semilente and ultralente for rapid onset and prolonged action (35-40). In 1956, Frederick 
Sanger and co workers elucidated the amino acid sequence of insulin, which was found to 
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be a two chain polypeptide having 51 amino acids (41, 42). The A-chain has 21 amino 
acids and the B chain has 30 amino acids. In 1958, Sanger was awarded the Nobel Prize 
in Chemistry for this work (43). Until then, the main source of insulin was pork or beef. 
Pork and beef insulin are found to be slightly different from the human insulin. Pork 
insulin has alanine in place of threonine at the B-30 position, whereas, the beef insulin 
differs in three amino acids. Thus pork insulin is more homologous to human insulin. 
However, due to differences in the amino acid sequences and presence of other 
impurities, these insulin formulations were responsible for a lot of hypersensitivity 
reactions (41, 42). 
 
The knowledge of amino acid sequence made it possible to chemically synthesize 
human insulin. In 1963, Meienhofer et al. and Katsoyannis et al. successfully synthesized 
human insulin (44-49). Kung et al. also synthesized human insulin in 1966 (50-53). 
However, the amounts were never sufficient for a clinical trial and therefore, pork and 
bovine insulin remained in continuous use. The development in analytical and 
purification techniques in the 1960s led to the production of a much purer form of these 
animal insulins, thus reducing the cases of hypersentivity and antigenisity in the human 
beings. In 1967, Steiner and Oyer published the biosynthesis of insulin and described that 
insulin is synthesized as proinsulin in the beta cells of pancreas, and the enzymatic 
conversion of proinsulin in the storage vessels produces insulin (54, 55). Dorothy 
Crowfoot Hodgkin, who had been awarded a Nobel Prize in Chemistry in 1964 for the 
development of crystallography, later elucidated the spatial conformation of the insulin 
molecule (43). X-ray crystallography was further used by Adams et al. to determine the 
structure of insulin crystals (56). 
 
Radioimmunoassay, for determination of very low concentrations of insulin in 
diabetic subjects, was developed by Rosalyn Sussman Yalow and Solomon Berson. In 
1977, Rosalyn Sussman Yalow was awarded the Nobel Prize in Medicine for her work on 
insulin (5). In 1979, Inouye et al. completed enzymatic semi-synthesis of human insulin 
by using porcine insulin as a starting material. This technique immobilized trypsin, which 
was helpful for continuous production of insulin (57-59). Hence, industrial production of 
human insulin was finally feasible. 
 
The 1970s was also an era of rapid advances in recombinant DNA technology 
which helped in the development of new methods for biosynthesis of human insulin. 
Genentech Inc. in 1978 used genetically engineered Escherichia coli to produce two 
chains of insulin separately and then joined the two chains chemically to produce human 
insulin (60). Novo Nordisk in 1982 commercially launched the first human insulin which 
was produced by the semi synthetic method (61). However, soon after, in the same year, 
Eli Lilly used Genentech’s method and got approval from the US FDA to market the 
human insulin - the first human protein produced by the recombinant DNA technology. 
 
1.2.1 The structure of human insulin 
 
The primary structure of human insulin consists of two polypeptides (Figure 1-1). 
The shorter chain A, which consists of 21 amino acids (A1-A21) and the longer chain B 
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Figure 1-1 Structure of human insulin 
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consists of 30 amino acids (B1-B30). The chains are connected together by two inter 
chain disulfide bonds between A7 and B7, and A20 and B19 cystines. In the A chain, an 
intra-chain disulfide bond is also present between A6 and A11 cystines. The amino acids 
of the two chains also interact with one another by non covalent bonds. 
 
In three dimensional conformation of human insulin, the A chain contains two 
alpha helix segments-one from A2 to A8, and the another from A13 to A20. These two 
alpha helices are antiparallel. The N-terminal of B chain contains an alpha helix from B9 
to B19, whereas, B21 to B30 forms a beta strand (62, 63). Wollmer et al. and Derewenda 
et al. explained that the A chain and the B9 to B19 structural units of B chain are stable, 
whereas, the conformations of B1 to B8 and B25 to B30 change in the presence of certain 
chemicals like phenols. In presence of phenol, the B1 to B8 segment extends to form the 
alpha helix (64-66). 
 
Human insulin exists in different forms, depending on the insulin concentration, 
pH and presence of zinc ions. Monomers, i.e. single unit of insulin are only present at 
very low concentration (<0.1 µM or 0.6 mg/L) (67). 
 
1.2.2 Insulin and its aggregates 
 
The insulin solution exits in a complex and dynamic state of equilibrium. Based 
on the insulin concentration, pH and presence of other ions, insulin may be present as 
monomers, dimers, tetramers or hexamers, which may further form insulin hexamer 
associates (67-71). 
 
Insulin in solution at very low concentrations (< 0.1 μmol ~ 0.6 μg/ml) exists as 
monomers (single units) (63, 67, 71). Insulin in blood is also found in predominantly 
monomeric form, which is also considered as the physiologically relevant form. Insulin 
monomer, due to its non-polar surface forces and hydrogen bond formation potentials, 
has a strong tendency to associate and form compact dimers (71). The dimers exist in a 
state of equilibrium with monomers and hexamers (71). The major interaction in 
monomers to form dimers occurs at B8, B9, B12, B13, B16, and C terminus segment B23 
to B28. The two COOH-terminal strands of B chain are arranged in the form of 
antiparallel beta sheets. 
 
The major interaction in monomers to form dimers occurs at B8, B9, B12, B13, 
B16, and C terminus segment B23 to B28. The two COOH-terminal strands of B chain 
are arranged in the form of antiparallel beta sheets. This allows close association of non-
polar forces and formation of four hydrogen bonds between B24 and B26 amino acids 
(71). In acidic solutions (below pH 4), the insulin molecules are predominantly in dimeric 
state. The dimers are flexible in nature and are prone to degradation, deamidation and 
fibrillation in an acidic environment. This may be due to the interaction of exposed non-
polar surfaces which may interact and form heterogeneous aggregates and fibrils (67, 71). 
 
The insulin hexamer, formed by the association of three dimers, is a nearly 
spherical structure with a height of approximately 35Å and a diameter of 50 Å (71). The 
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center of this spherical hexamer form is a polar channel. Two zinc ions form a co-
ordination bond with the imidazole group of B10 histidine, which is present in the 
centrally located polar channel of the hexamer. The addition of zinc ions or other divalent 
transition metals promote the formation of hexamers (72, 73). 
 
In solution, the insulin hexamers bind with metal ions and exist in three 
conformational states, namely, T6, T3R3 and R6. In solution, the three states of hexamers 
exist in a dynamic equilibrium. Addition of inorganic anions or adequate concentration of 
phenol like molecule shifts this dynamic equilibrium from T6 to T3R3 (72). Higher 
concentration of phenols further strengthens the hexamers by shifting the equilibrium 
completely toward the conformational state R6 (74). In all of these three conformations, 
the A chains folds into a helix-loop-helix motif, A2 to A8 and A12 to A19 forms two 
helical structures (74). The B chain can take two different conformations. The B chain in 
T state contains “an extended N-terminal arm”, a central α-helix (B9 to B 19), a type I 
turn (B20 to B23) and a C terminal B strand “In the R state, residue B1 to B9 takes up a 
helical conformation to form a region of alpha-helix contiguous from B1 to B9” (74). 
 
1.2.3 Insulin zinc and different state 
 
In T6 state, the six monomeric units exists in the T fold, whereas, in T3R3 state, 
three monomeric units exist in T fold and three exists in R fold. In the R state, the all six 
monomeric units exist in the R fold. Brange et al. reported that A13, A14, A17 residue of 
A chain are involved in hexamer formation (71). In B chain, B1, B2, B4, B10, B13, B14, 
B17, B18, B19, B20 residues play a major role in hexamer formation. Zinc ions are key 
to formation of hexamers and further stabilizing them. Kadima et al. reported that T6 or 
two zinc “insulin hexamer is an assembly of three equivalent dimers related by 3 fold 
axis of symmetry” and an identical symmetry is expected in solution (75). In crystalline 
rhombohedral state of T6, there are two equivalent zinc binding sites. These two sites are 
present along the three fold axis of symmetry. In each of these two sites, there are three 
equivalent histidine B10 residues. Zinc forms coordinate bonds with nitrogen of 
imidazole side chain of these histidine. The other coordinate positions of the zinc are 
occupied by three water molecules or other ligands (75, 76). Hence, in T6 conformation 
state, each of the two zinc ions are coordinated with nitrogens from three His-B10 
imidazole groups and three water molecules. However, Emdin et al. reported that T6 
states are capable of binding more than two zinc ions. The middle of the hexamer also 
contains a calcium binding site. The calcium binding site is formed by the six carboxylate 
groups of B13 glutamate residue, and can bind three calcium ions (75). 
 
The dimer in T6 hexamer also interacts through non-polar surfaces. The alanine 
B14 and leucine B17 residues of the dimer in T6 hexamer create non-polar surfaces, 
which further help in contact of dimers. The B1 to B8 residues are in an extended or non-
helical conformation. It has also been reported that phenylalanine B1 from one dimer 
interacts with leucine A13 and tyrosine A14 from the other dimer (74). Phenols and 
similar aromatic alcohols like cresols, and chloride ions in concentration above 6% 
dramatically change the structure of insulin hexamer (67, 76). 
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Insulin crystals can be grown in the presence of chloride ions, and these crystals 
are similar to crystals of two zinc insulin. However, chloride ions induce a helical 
structure in extended residues, B1-B8 of three monomers in a hexamer, thus producing 
T3R3 conformation (67, 76). Some other lycotrophic anions like SCN-, I-.Br- (INS-28, 
11) have also been reported to induce this T to R conformation in three of the six 
monomers, thus giving a T3R3 conformation. This T3R3 conformation gives a new 
conformation to histidine at B5, which creates an additional zinc binding site (67). Two 
more zinc ions can coordinate with nitrogen of insulin hexamer in T3R3 conformation 
and hence T3R3 is also known as four-Zn insulin. However, Coffman et al. reported that 
in crystals, the four-Zn insulin hexamer or T3R3 state does not bind four zinc ions. They 
further reported an occupancy of 2.67 (77). 
 
Monoclinic crystals are obtained on crystallization of insulin in the presence of 
0.5% phenol (67). Phenols induce T to R conformation change in all six monomers of the 
hexamer, where the hexamer in these monoclinic crystals are in the R6 state. In helical 
‘R’ state, all the insulin monomer subunits have the B1 to B19 helical structure (78). 
Since all the subunits are identical in R6 conformation, the two fold symmetry axis are 
restored (67). R6 conformation has two zinc ion binding sites, which lies on the 
symmetry axis as in T6. These two sites are again formed by His B10 imidazole, but 
interact with only one water molecule (78). 
 
Phenol induced R6 hexamer also contains six identical hydrophobic pockets for 
binding of six phenol molecules (78). One side of the pocket is bound by B chain helix 
and A-chain bound the other three sides (78). Phenol molecules specifically bind to each 
of the six subunits at these pockets. The carbonyl oxygen of cystine A6 and amide 
nitrogen of A11 cystine forms hydrogen bond with hydroxyl group of phenol (67). Each 
of the His B5 of R6 interacts with the aromatic ring of phenols through Van der Waals 
forces. This blocks the axial zinc binding sites of His B5 in R6 conformation. Therefore, 
only two zinc binding sites are available (67). 
 
It has been reported by several groups that T (extended) and R (helical) 
conformation interconvert in solution (78). Furthermore, these different conformations 
(T6, T3, R3, R6) exhibit different spectroscopic properties (78). Based on various studies, 
Kaarsholm et al. also believes that the structure of T6 and R6 are identical in solution and 
in the crystalline state (78). 
 
In 1961, Schlichtkull reported that a number of metal ions such as Cd2+, Co2+, 
Cu2+, Ni2+, Fe2+, and Mn2+ can be accommodated by the zinc binding site of T6 (2-Zn 
insulin hexamer) (79). Roy et al. in 1990, investigated the existence of a zinc-free R6 
hexamer in solution (80). Kadima et al. reported the formation of Cd2+, Ni2+ and Fe2+ 
substituted R state hexamers (75). In 1987, Wollmer et al. showed that placing nickel (II) 
in zinc sites impeded the transition of T to R conformation (81). In 1956, Schlichtkrull 
was studying the growth of very small insulin crystals, which could be injected for the 
treatment of diabetes, when he discovered – insulin hexamer (82-85). The monomer of 
insulin has 23 polar residues. All of these polar residues are present on the surface of the 
 9 
the hexamer, the two zinc ions are located on the 3-fold axis of symmetry. One is located 
8Å above and the other 8Å below the 2 fold axis (71, 86). 
 
1.2.4 Insulin zinc interaction and pH 
 
It is well established that insulin in the solution in neutral and alkaline pH range, 
and in the presence of zinc, predominantly exists as hexamers of molecular weight of 
approximately 36,000 (86). The proportion of hexamers also increases in this pH range as 
the zinc concentrate increases up to two zinc ions per hexamer (86). Hallas–Mollar et al. 
and Cunningham et al. reported that as the pH increases from pH 4.5 to 8.0, additional 
seven ions of zinc can associate with a hexamer (86, 87). Blundell et al. reported that at 
neutral pH, as the zinc concentration increases above two zinc atoms of zinc per hexamer, 
a 72,000 dalton unit starts appearing (86). They further reported that as the zinc amount 
increased above six atoms per hexamer, the distribution of insulin units became 
polydisperse and units with 200,000-3000,000 daltons occurred predominantly. As the 
pH was increased above pH 8.0, even in high concentration of zinc, these polymers 
dissociated in 36,000 dalton hexamers in the pH range of 9-10 (86). 
 
1.2.5 Insulin mechanism of action and degradation 
 
Insulin binds to insulin receptors, which are located on cell membranes. The 
insulin receptors are present on all the cells; however, their density is highest on liver and 
the adipose cells. The insulin receptors are heterotetrameric glycoprotein consisting of 
two extracellular α and two transmembrane ß subunits. These subunits are linked together 
by disulfide bonds. The insulin binding sites are present on α subunits, while the have 
tyrosine protein kinase activity. The insulin binds to α subunits and induces aggregation 
and internalization of receptor and the bound insulin molecules. This activates a cascade 
of reactions resulting in the metabolic activities of insulin (88-92). 
 
The internalized receptor insulin complex is either degraded intracellularly by 
insulin-degrading enzyme (IDE) or this complex is translocated back to the surface of the 
cell membrane, from where it may be released in systemic circulation. Insulin has plasma 
half life of approximately 4 to 5 minutes (93, 94). The liver and the kidneys are two 
major sites for insulin clearance from the systemic circulation (95-99). The receptor 
mediated clearance of insulin by hepatic and renal cells follow similar cellular 
mechanisms (100, 101). The insulin-degrading enzyme (IDE) is the major enzyme 
responsible for degradation of insulin. The IDE mediated degradation of insulin generates 
various products which have been well characterized (93, 102-108). It has been 
established that IDE recognizes the three-dimensional configuration of the insulin rather 
than specific peptide bonds (93, 106, 108). Stentz et al. further reported that IDE 
recognizes α-helical region around leucine-tyrosine bonds, and the major peptide bond 
cleavage sites of insulin are A 13-14, A l4-I6, B 9-10, B 13-14 and B 16-17 (109). These insulin 
fragments may not only contribute to immunoreactivity, but may also bind to insulin 
receptors to produce biological activity (110). 
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1.3 Treatment of diabetes 
 
Diabetes mellitus, depending on the type and stage of the disease, is treated with 
physical exercise, dietary control, oral hypoglycemics agents alone, or a combination 
therapy of insulin and oral hypoglycemics agents, or insulin therapy alone (111-114). 
Diabetics who suffer from the type-1 disease require insulin therapy for their survival. A 
new class of drug called amylin analogues, e.g. pramlantide acetate has also been 
recommended as an adjunct to insulin injections for the management of blood glucose 
concentrations in type-1 diabetic patients (115-117). 
 
Depending on the stage at which the disease is diagnosed, diabetics who suffer 
from type-2 disease can be treated with an appropriate diet and proper exercise, or a 
monotherapy or a combination therapy of oral hypoglycemic agents (114). However, 
most of the type-2 diabetes patients may need insulin at some stage of their treatment for 
achieving the targeted glycosylated hemoglobin (HbA1c) concentrations of less than 7% 
(i.e. mean plasma glucose concentration equal to 170 mg/dL or 9.5 mmol/L) (118, 119). 
 
The target of insulin therapy (either alone or in combination with other 
antidiabetic drugs) is to mimic the physiological release and concentrations of insulin. 
However, the tendency of regular human insulin to self associate after a subcutaneous 
injection, cannot allow it to mimic physiological required insulin secretion following 
food intake (113, 114). This is because of formation of hexamer from regular human 
insulin at the site of injection. These hexamers cannot cross the capillary barriers due to 
their size. The hexamers have to dissociate first into dimers and then into monomers to 
cross the capillary barrier and get absorbed into the blood stream prior to their action on 
insulin receptors. This process of dissociation of hexamers into monomers leads to a 
delay in the onset of action (114). 
 
The onset of action with a formulation of regular human insulin is reported to be 
from 30 min to 1 hour and the duration of action of insulin in the body is reported to be 2 
to 6 hours (114). Since the duration of action of insulin is not short, it cannot mimic the 
rapid decline of the physiological insulin concentrations after the meals. Table 1-1 details 
various regular human insulin preparations. Intermediate acting and long acting insulin 
formulations (NPH+ Lente) have been dispensed for basal insulin requirements. 
However, these formulations are associated with slow onset of action because of further 
stabilization of slow dissociating hexamers, and these formulations also show a 
pronounced peak leading to hypoglycemia in diabetic subjects. Furthermore, since the 
formulation like Lente and Ultralente are suspensions, the duration of action of these 
formulations varies significantly within and between individuals (114). 
 
The goal of treating diabetes is to maintain a tight control on the blood glucose 
concentrations. It is difficult to achieve the tight glycemic control in diabetic subjects 
who are on regular human insulin therapy. This may lead to poor management and 
further progression of the disease (114). There is a strong need to develop an insulin 
formulation which can mimic physiological insulin action. The interest in producing the 
time action profile of injected insulin as per requirement of the diabetic patient is the 
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Table 1-1 Insulin and modified insulin preparations 
 
 
Type 
 
Description 
 
Examples 
 
Action (hours) 
   Onset Duration 
 
Rapid-acting 
 
 
Modified insulin 
 
Lispro (Humalog) 
 
> 15 min 
 
3-5 
Aspart (Novolog) 
Glulisine (Apidra) 
 
Short-acting 
 
 
Regular insulin 
Humulin R  
0.5-1 
 
5-8 
Novolin R 
 
Intermediate-acting 
 
 
NPH or Isophane 
Humulin N  
1-3 
 
14+ Novolin N 
Lente Humulin L 1-2.5 14+ 
 
Long-acting 
 
 
Modified Insulins 
Glargine  
1-2 
 
20-24 Detemir 
 
 
Source: Chen Q. Controlled release of insulin from a novel biodegradable injectable 
gel system.2006, Doctoral Dissertation; Electronic Resources: 
http://sunzi1.lib.hku.hk. Last accessed: October 30th, 2007. (113). Used with 
permission. 
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driving force for the development of modified insulins or insulin analogues (114). 
 
NPH: Neutral Protamine Hagedorn insulin. The US FDA has approved five 
modified human insulin or insulin analogues. Table 1-1 lists these insulin analog 
preparations. All the formulations are to be administered via a subcutaneous injection. 
These insulin analogues can further be divided into two categories: Rapid acting insulin 
analogues, which attempt to reproduce the rapid secretion of insulin after meals, and the 
long acting insulin analogues (basal Insulin), which attempt to reproduce the basal 
concentrations of insulin that is secreted between meals during fasting and nocturnal 
phases (120, 121). 
 
There are three rapid acting insulin analogues approved by the US FDA. Insulin 
Lispro (Humulog®, Elli Lilly), Insulin aspart (Novolg®, Novo Nordisk) and Insulin 
glulisine (Apidra®, Sanofi-Aventis). These insulin analogues bind to the receptor of the 
native human insulin and produce physiological effects similar to the endogenous insulin 
(122). These insulin analogues have been generated and produced by using recombinant 
DNA technology (122). The structure of insulin in the above mentioned analogues has 
been modified to achieve the desired pharmacokinetic and pharmacodynamic effects 
(122). 
 
Lispro was the first rapid-acting human insulin analogue that was approved by the 
US FDA for treating type-1 and type-2 diabetes in humans (113, 123). It is a rapid acting 
insulin analogue which is effective for a short duration of time. The glucose lowering 
effect onset is from 5 to 15 minutes, and peaks in 30 to 90 minutes, and lasts for 4 to 6 
hours (32, 113). The structure of Lispro is similar to endogenous human insulin except at 
two amino acid of the B chain. Lispro has been generated by inversion of amino acid 
lysine (B29) with proline, and proline B28 with lysine (123-125). 
 
These modifications have affected the binding of Lispro with insulin receptor, but 
only slightly. However, the effects of insulin Lispro on biochemical signaling, glucose 
and amino acid uptake are similar to regular human insulin (113, 123). The minor change 
in the structure sequence destabilize the dimers by disrupting hydrophobic interaction and 
hydrogen bonding between the monomers (123). Hence Lispro monomers have a low 
propensity to self-associate and form dimers. It has been shown that in the presence of 
zinc and phenol, which are required to stabilize the Lispro formulation at neutral pH, 
Lispro forms hexamers (125). However, unlike human insulin where up to six phenol 
molecules bind to the hexamer, only 3 phenol molecules bind to hexamers of Lispro 
(125). The association of monomers in Lispro hexamer has been described as relatively 
weaker than that of regular human insulin hexamers. Therefore, after injection, the 
phenols diffuse away leading to conversion of loosely associated hexamer directly into 
monomer (123, 125). The dissociation of hexamer into monomer has been described as 
the rate limiting step in the absorption of insulin from the site of injection (123). The 
elimination half-life of Lispro after a subcutaneous injection has been reported as 60 
minutes. This is significantly shorter than the half-life of regular human insulin (90 
minutes) after a subcutaneous injection (123). 
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Lispro is recommended for type-1 and type-2 diabetic subjects, and should be 
injected within 15 minutes before meals and if necessary immediately after meals. 
Intravenous Lispro injection can be given in case of an emergency to deal with keto-
acidosis or surgery (123). In different trials, it has been shown that Lispro is safe for fetus 
and new born, if it is injected in gestational diabetic subjects; however, its use is not yet 
recommended. Lispro can be mixed with NPH to form premixed Lispro NPH. The 
combination of Lispro-NPH addresses the need of both bolus and basal therapy of 
diabetic subjects (123). 
 
Insulin Aspart is the second rapid acting insulin analogue approved by the US 
FDA. Similar to Lispro, it has faster onset and shorter duration of action (125, 126). 
Insulin Aspart is created by substitution of the proline at B28 with aspartic acid (113, 
124, 126). At the physiological pH, a negative charge is generated on the insulin 
molecule. This negative charge helps in repulsion of the monomers and reduces the 
tendency of the monomer to self associate into hexamers. Replacement of proline with 
aspartic acid also leads to a loss of Van der Waals forces, necessary for self association. 
This leads to rapid dissociation of hexamer to monomer resulting in rapid absorption. 
Like Lispro, Insulin Aspart is recommended for the treatment of both type-1 and type-2 
diabetic subjects. It is recommend to be injected immediately before meals and its 
duration of action lasts for approximately 2 to 4 hours (126). 
 
Insulin glulisine (Apidra®, Sanofi-Aventis) is another rapid-acting insulin 
analogue. In insulin glulisine, the asparagine at position B3 is replaced by lysine, and the 
lysine at position B29 has been replaced by glutamic acid (127). It has also a fast onset 
and short duration of action. One more modified insulin; is insulin glargine (Lantus®). 
However, it recommended for maintaining basal insulin concentrations (121, 128). 
Insulin glargine has been altered at two different positions. In A-chain, at position 21, the 
asparagine has been substituted with glycine, thus imparting more resistance to 
deamidation in an acidic environment, and providing more stability (128, 129). The C-
terminus of the B-chain has elongated by the addition of two arginine molecules. This 
addition of two positive charges by the addition of arginines shifted the isoelectric point 
of the modified insulin glargine from pH 5.4 to 6.7 (129). These modifications have made 
it possible to formulate insulin glargine into a slightly acidic stable solution, which is 
easy to inject and improve dose reproducibility. This insulin glargine solution forms 
stable hexamers, which precipitate at neutral pH at the subcutaneous site of injection, 
thus forming a depot of microprecipitates of the modified insulin glargine which then 
dissolves at a steady rate for prolonged period of time (121, 129). 
 
Insulin detemir (Levemir®, Novo Nordisk) is another modified recombinant 
human insulin whose structure has been altered such that upon subcutaneous injection, it 
gives a slow and an extended effect. In insulin detemir; the B-30 threonine of human 
insulin has been deleted (130, 131). A C-14 carbon fatty acid, i.e. myristic acid has been 
attached to B-29 lysine residue (130, 131). At neutral pH, insulin detemir is soluble and 
does not precipitate during storage, administration or absorption (132-135). It has been 
reported that insulin detemir, due to its hydrophopic nature, has a tendency to bind with 
proteins like albumin, which are present at injection sites and in blood. This reduces its 
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clearance and increases the half-life; thus leading to the extension in duration of action. 
Hence, insulin detemir is recommended for basal insulin therapy. It should be injected 
once or twice daily (132-135). Both insulin detemir and insulin glargine are 
recommended for the treatment of both type-1 and type-2 diabetic subjects (130). 
 
 
1.4 Non-invasive insulin delivery systems 
 
Subcutaneous injection of insulin has been a satisfactory mode of insulin therapy 
for a vast majority of diabetes subjects. However, the use of these subcutaneous 
injections may cause hyperinsulinemia, which may lead to hypoglycemia and diabetic 
micro and macro angiopathy (136, 137). Further, these subcutaneous injections of insulin 
are also associated with pain, inconvenience, physiological stress, high cost, difficulty in 
handling insulin, localized insulin deposition leading to local hypertrophy, and fat 
deposition at the site of injection (136, 138). Hence, during recent years, a great deal of 
interest has been shown for the development of novel ways to deliver insulin 
noninvasively. 
 
Scientists in academic institutions as well as in the pharmaceutical industry are 
working on different drug delivery technologies including oral, nasal, buccal, pulmonary, 
transdermal, rectal and ocular to get a viable and feasible noninvasive insulin dosage 
form (136, 139, 140). 
 
1.4.1 Oral insulin delivery of insulin 
 
The conventional oral route is the method of choice for delivery of most drugs 
because of its acceptability by patients and ease of manufacturing. Further, in the case of 
successful oral insulin delivery, it may mimic physiological pattern of insulin leading to 
better glucose homeostasis (136, 141). However, efficient oral insulin delivery is 
challenging because of enzymatic and acidic degradation, thus leading to poor and 
unpredictable absorption and bioavailability. Therefore, for successful oral delivery, 
insulin should be protected against acidic and enzymatic degradation. Moreover, its 
epithelial permeation should be enhanced and bioactivity should be conserved during the 
formulation process (136). Various groups have tried different pharmaceutical 
approaches to maximize insulin stability and bioavailability for effective oral insulin 
delivery. Some of these approaches include enzyme inhibitors, absorption enhancers, 
mucoadhesive polymer systems, particulate carrier delivery systems and targeted delivery 
systems. 
 
Enzyme inhibitors: Insulin is extensively degraded by gastrointestinal enzymes 
such as trypsin, α chemotrypsin and elastase (136, 142). The effects of intestinal 
degradation of insulin in rats have been evaluated in the presence of different enzyme 
inhibitors like sodium glycocholate, camostate mesilate, bacitracin, soybean trypsin 
inhibitor, and aprotinin. None of these enzyme inhibitors have been reported to be 
effective in the small intestine, and only some of these like sodium glycocholate, 
camostate mesilate, and bacitracin were found to be effective in showing some 
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improvement in absorption and bioavailability enhancement from the large intestine of 
rats. However, in general, these enzyme inhibitors are considered highly toxic and they 
may also affect the normal degradation and digestion of food proteins. 
 
Absorption enhancers: Absorption enhancers improve the paracellular and 
transcellular transport of drugs in the gastrointestinal tract (GIT) by changing the 
membrane fluidity, decreasing mucus viscosity, opening tight junctions, and leakage of 
proteins from the membranes (136, 143). For improving the absorption of insulin, various 
non-specific permeation enhancers like bile salts, fatty acids, surfactants, salicylates, 
chelators, and zonula occluden toxin have been tried (144-147). However, it has been 
reported by Morishita et al. that the absorption enhancers increase insulin efficacy more 
effectively in the colon than in small intestine (147). Furthermore, since absorption 
enhancers increase permeation of cell membrane and open the tight junctions not only for 
insulin and other peptides, but also for undesirable molecules which are present in the 
GIT, their use may not be safe for chronic use (136). 
 
Emisphere Technology, Inc, has developed oral capsules, called Eligen™ , which 
use non-acylated amino acids as the carriers for transport of insulin. This oral insulin 
delivery system is currently undergoing Phase II clinical trials (148, 149). 
 
Mucoadhesive systems for oral insulin delivery have also been developed. These 
systems increase the residence time of insulin at the site of absorption, strengthen the 
contact with the mucus, and localize the drug delivery system thus increasing the drug 
concentration gradient (136). Morishita et al. studied poly (methacrylic acid-g-ethylene 
glycol) [P(MAA-g-EG) polymers for oral insulin delivery and found that these 
mucoadhesive systems with smaller sized microparticular insulin loaded polymer system 
showed approximately 10% bioavailability of insulin after oral administration in diabetic 
rats (150). In a similar study, lecithin conjugated alginate microparticles, mucoadhesive 
chitosan nanoparticles of insulin and insulin tablets formulated with mucoadhesive 
thiolated (thiomers) seemed to increase the absorption of insulin via rat intestinal mucosa 
(151-154). These mucoadhesive delivery systems are considered to be effective in 
increasing the absorption of drug molecules susceptible to proteolytic degradation, 
however, their long term safety data in humans is warranted (155). 
 
Colloid carrier delivery systems like microemulsions (156) liposomes (157) 
polymeric micelles (158) and polymeric nanoparticles and polymeric microparticles have 
been studied to improve the insulin delivery via oral route using specific sites like payer’s 
patches. Other systems for oral administration of insulin that have been studied are dry 
insulin emulsions, solid-in-oil-in water emulsion of insulin, and microemulsion of insulin 
(159-162). These systems have demonstrated an improved efficacy of the orally 
administered insulin. 
 
Cortecs International, Inc. in collaboration with Provalis PLC has developed oral 
microemulsions of insulin called Macrulin™, This system is in Phase II clinical trials 
(162-165). 
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Different types of liposomes have also been studied for their potential as carrier 
for oral administration of insulin. For example, Katayama et al. reported double 
liposomes of insulin with aprotinin, whereas Degim et al. reported similar liposomes of 
insulin with sodium taurocholate and found that blood glucose concentrations decreased 
significantly after oral administration in rats (166, 167). Goto et al. prepared fusogenic 
liposomes of insulin with envelope glycoprotein of Sendri virus (168). These liposomes 
were directly administered into the lower intestine of rats and were found to improve 
insulin absorption. Significant decrease in blood glucose concentrations were observed in 
these rats (162, 168). 
 
Ye et al. reported, layer-by-layer, a new method of insulin loading in alginate – 
chitosan microcapsules. Nanocapsules of insulin made with polyethy-2-Cyano acrylate 
for oral delivery have also been reported. Chitosan microspheres with microadhesive 
properties and permeation enhancing effect have also been studied (169). 
 
Enteric coated microspheres, using Eudragit S100 and nanoparticles using 
polymethacrylic acid-chitosan- polyethyle glycol have been investigated by Sajeesh et al 
and reported to be potential carriers for oral insulin delivery (170). Though some success 
has been achieved with these systems, there are still limitations such as poor drug 
incorporating efficacy, erratic drug release, particle aggregation, and low bioavailability, 
which should be addressed prior to further development (170). 
 
Due to benefits of drug delivery to the colon, oral insulin delivery targeted in the 
colon has been extensively studied. Insulin delivery system with absorption enhancers 
like sodium glycocholate alone (171) or in combination with polyethylene oxide has 
shown prolonged absorption of insulin from the colon. Novel azopolymers coated pellets 
have been developed by Tozaki et al. for colon delivery of insulin (172). 
 
Peyer’s patches, which are present in small intestine and play a major role in 
absorption, are also potential targets for oral delivery of insulin. Joseph et al. prepared 
microspheres of PLGA for oral delivery of insulin in mice (173). The microspheres 
(approximately 1 micron size) were supposed to be absorbed through Peyer’s patches and 
reported to have very significant effect on lowering of blood glucose concentrations 
(173). 
Receptor mediated transcytosis is one more potential approach for the oral 
delivery of insulin. This approach does not affect the structure of plasma membranes or 
the paracellular junctions, and thus may be safer for chronic use. Transferrin receptors are 
considered good candidates for oral delivery of insulin because of their high density in 
the human GIT epithelium since transferrin is a natural transport protein. Xia et al. 
prepared insulin transferrin conjugates and reported prolonged hypoglycemia effect after 
oral administration in diabetic rats (174). 
 
The buccal route of delivery for peptides and proteins like insulin is also a 
promising and widely investigated route of administration because of its accessibility to 
systemic circulation through the jugular vein. Therefore, the hepatic first pass is easily 
circumvented and higher bioavailability can be achieved through the use of this route. 
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Moreover, using this route, insulin administration is painless, enzyme activity is low and 
the system can be easily removed in case of adverse effects. The peptide absorption 
across the buccal membrane occurs via passive diffusion (175-177). Therefore, 
absorption enhancer, which are non irritant and not bitter, can be used to improve the 
permeability and hence enhance the bioavailability of insulin. Morishita et al. reported 
the preparation of Pluronic F-127 gels consisting of insulin and unsaturated fatty acids for 
buccal delivery (177). They showed that the gels prepared with Pluronic F-127 
containing unsaturated oleic acid improved the bioavailability of insulin significantly in 
rats (9 ± 7.9%) (177). 
 
Generex Biotechnology, Inc. has developed an oral insulin system called Oral-
lyn™. The system is a micellar solution of insulin, which is to used as a buccal spray 
(148, 178, 179). This system has been marketed in India and Ecuador. 
 
Transferosomes, which are ultra flexible and highly deformable lipid vesicles like 
liposomes, consisting of cholesterol, soybean phosphotidyl choline and sodium 
deoxycholate have been developed by Yang et al. for buccal delivery (180). They have 
shown that the relative bioavailability of insulin from the buccal transferosomes was 
19.78% in rabbits. Nagai et al. have shown promising results using mucoadhesive 
nanoparticles of insulin in beagle dogs (181). Mucoadhesive buccal tablets made of 
Carbopol-934 with absorption enhancers have been reported by Venugopalan et al.(182). 
Xu et al. further reported the development of buccal spray of insulin with improved 
hypoglycemia effect lasting for up to 5 hours (183). 
 
1.4.2 Nasal delivery of insulin 
 
Nasal cavity provides a large surface area, and delivery via nasal route avoids 
hepatic first pass metabolism. Therefore, nasal insulin delivery systems have been widely 
studied. Furthermore, it has been reported that nasal delivery of insulin resembles the 
physiological pulsatile pattern of insulin release (184). Various absorption enhancers like 
sodium deoxycholate in combination with cyclodextrins, soybean derived sterol mixtures 
have been used with insulin to increase its absorption via nasal membrane (185, 186) in 
rats and rabbits. This approach has shown significant absorption promoting effect. 
However, absorption enhancers may cause irreversible damage to the nasal mucosa upon 
long term use. Therefore, long term safety of these delivery systems should be studied 
(187). Nasal mucoadhesive systems may increase the retention and contact time in the 
nasal cavity, thus improving the total absorption (188, 189). Najafabadi et al. prepared 
mucoadhesive Carbopol based gel spray and reported that upon nasal administration of 
the gel, the relative bioavailability of insulin in rabbits was 20.6%. Some other groups 
have also developed chitosan bioadhesive gels (190), chitosan nanoparticles (191) and 
chitosan microspheres (192) for nasal delivery of insulin in animals. They have all found 
that the absolute bioavailability of insulin has been increased significantly after nasal 
delivery. 
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Bently Pharmaceuticals, Inc. has developed Nasulin™, a nasal spray of insulin, 
which utilizes absorption enhancers for increasing the bioavailability of insulin (148, 178, 
179). This system is in Phase II clinical trials. 
 
1.4.3 Pulmonary-lung delivery of insulin 
 
Pulmonary administration of proteins and peptide is considered very promising 
because of large surface area (140 m2) offered by the lungs, a thin alveolar epithelium, a 
lower metabolic activity of enzymes relative to GIT, and by pass of the first pass hepatic 
effect (136). Spray-dried insulin alone or in combination with other excipients like 
absorption enhancers and other particulate formulations like liposomes, nanoparticles, 
and nanospheres have been tried to deliver insulin successfully in animals via pulmonary 
route (136). Kwo et al. attempted pulmonary delivery of micro crystals of insulin and 
reported hypoglycemic effect lasting for seven hours in rats (193). Surendrakumar et al. 
prepared co-spray dried insulin powder and hyalouronic acid for inhalation and studied 
the insulin concentration in beagle dogs (194). They reported that the insulin-hyalouronic 
acid-Zn particles, after pulmonary inhalation, lasted for 4 to 5 hours. Mitra et al. studied 
co-administration of insulin with absorption enhancers like 1-2 dipalmitoyl 
phosphatidylcholine and showed a significant reduction in blood glucose concentrations 
after pulmonary delivery (195). Some other studies reported the use of Span 85, 
bacitracin, and citric acid and cyclodextrin derivatives as absorption enhancers of insulin 
via pulmonary route (195-197). 
 
PLGA particles of insulin, like PLGA nanospheres, PLGA microparticles with 
cyclodextrins have also been prepared and reported to be effective in inducing 
hypoglycemia effect for 4 to 5 hours (198-200). 
 
Exubera®, which was launched by Pfizer in January 2006 as the first non invasive 
insulin delivery system was a milestone in the development of noninvasive delivery of 
insulin. However, it was withdrawn from the market in October 2007. Though the major 
reason for withdrawal of the product from the market was economic loss, other issues 
such as occurrence of more cases of hypoglycemia (201, 202), dose optimization in 
smokers and asthmatic patients, issues such as development of antibodies against insulin, 
and effect of insulin on IGF-1 receptors and proliferation effects should have been more 
carefully studied and reported before marketing a pulmonary delivery system of insulin 
like Exubera® (201-205). 
 
1.4.4 Ocular delivery of insulin 
 
In 1931, Christie and Hanzal investigated the use of eye as potential delivery 
route for insulin for the first time (136). Ocular route provides the benefits of fast action, 
low immunological reactions, and by pass the first pass hepatic metabolism. However, 
pure insulin eye drops have low bioavailability (136). Hence, various research groups 
have reported the use of different absorption enhancers for ocular delivery of insulin. 
Yamamto et al. studied polyoxyethylene-9-lauryl ether, sodium glycocholate, sodium 
taurocholate, and sodium deoxycholate as absorption enhancers in eye drops of insulin, 
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and studied their hypoglycemic effect and safety profiles in rabbits for three months 
(206). Uses of fusidic acid, dodecylmaltoside, or tetradecyl maltoside as absorption 
enhancers for ocular delivery of insulin have also been reported (207). One of the issues 
with ocular delivery of insulin is low retention time of the formulation in the ocular 
cavity. Positively charged liposomes containing insulin have been formulated and have 
been reported to reduce the blood glucose concentration in rabbits to 65-70% of initial 
glucose concentrations, and the effect lasted for five hours (208, 209). Ocular inserts like 
Gelfoam® have been developed for prolonged release of insulin in the eye and the system 
has shown lowering of blood glucose concentrations (60% of initial concentrations) for 
up to 8 hours. 
 
1.4.5 Rectal delivery of insulin 
 
The hepatic first pass metabolism can be avoided using rectum as delivery route 
for insulin and this route is regarded as more physiological route for administration of 
insulin (136). Insulin suppositories have been developed and tested in rabbits and shown 
to have promising results (210). Further, absorption enhancers like sodium cholate 
sodium glycocholate, sodium taurodeoxycholate, sodium taurocholate, sodium 
deoxycholate and sodium salicylate have been tried in insulin suppositories prepared with 
Witepsol W 35 as base. Some of these formulations showed up to 50% relative 
hypoglycemic effect. Snail mucin has also been used as an absorption enhancer in 
glycerol gelatin suppositories of insulin by Adikwi et al.(211). They showed that blood 
glucose concentration reduced to 44% within two hours of application of these 
suppositories (211). Thermoreversible suppositories containing poloxomers, which 
convert to gels upon rectal application, have also been developed as rectal delivery 
system for insulin in animals (212). 
 
 
1.5 Controlled release of insulin  
 
Insulin, has been reported to be released in a pulsatile manner from isolated islets, 
perifused pancreas and in vivo (213). Therefore, for diabetic subjects, the ideal insulin 
delivery system should be capable of mimicking this natural pattern, i.e. the delivery 
system should have a sensing and auto shut off capability (113). Various research groups 
are investigating two kinds of glucose sensing insulin delivery systems. These are 
glucose sensitive hydrogels and artificial pancreas, i.e. closed loop delivery systems. 
 
1.5.1 Artificial pancreas 
 
These systems are also called closed loop delivery systems (113). These types of 
systems consist of a sensor, which remains in contact with blood or interstitial fluid, and 
measure the glucose concentrations in blood, and then communicate with an attached 
microcomputer. This microcomputer then communicates with the attached pump and 
modulates the release of insulin from the pump. Hence, the blood glucose concentration 
determines the release of insulin from the pump. However, there are limitations with 
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glucose sensing and regarding the glucose turnover and insulin stability in the pumps. 
These kinds of systems are still in the development phase (113, 214). 
 
1.5.2 Glucose sensitive hydrogels 
 
These are also called “smart gels” and have the capability of changing some of 
their properties in response to the glucose concentration in the surroundings. pH sensitive 
polymers immobilized with the glucose oxidase have been used in many investigations 
(113, 215, 216). When these systems encounter glucose, the glucose oxidase present in 
these systems oxidizes glucose to gluconic acid, thus lowering the pH. The change in pH 
may lead the polymeric gel to swell and expand or collapse and squeeze. This change in 
dimension of polymeric gel expansion or the squeezing are proportional to the glucose 
concentration present in the ambience and this modulates the release of insulin from the 
gels made up of these polymers. Catalase has been included in these kinds of systems to 
enhance the oxidation rate of glucose (113, 215, 216). 
 
1.5.3 Extended release of insulin 
 
The self regulating glucose sensitive insulin delivery systems are ideal form of 
insulin dosage form but they are difficult to develop and have certain limitations (113). 
Therefore, development of an extended release formulation of insulin, which can provide 
constant release of insulin for a prolonged period of time, is desirable. Long acting 
insulin like insulin glargine and insulin detemir, and intermediate acting insulin like NPH 
are available as substitutes of basal insulin. However, a daily injection of these 
formulations is required. This daily injection may not be tolerated by the diabetic 
subjects, who would need these injections for rest of their life. This may lead to poor 
patient compliance, which may further lead to poor management of diabetes. Hence, 
there is strong need to develop novel insulin formulation having prolonged action, 
requiring less frequent injections (113). 
 
Non-invasive insulin delivery systems for normal delivery of insulin are still 
under development. Various parenteral extended release delivery systems are also being 
considered for the prolong delivery of insulin (113, 217). 
 
Microparticles, including microspheres and microcapsules of nonbiodegradable 
polymer such as ethylcellulose, or biodegradable polymers such as PLGA have been 
prepared for prolonged delivery of insulin (113, 218-223). However, more focus is on the 
development of biodegradable microspheres. Despite being biodegradable, these 
biodegradable microspheres have some limitations like initial burst leading to 
hypoglycemia or a lag time in release (113, 221, 222). Yamaguchi et al. reported that 
addition of hydrophilic excipients like glycerol or water during the preparation of these 
microspheres can reduce the initial burst (113, 222). 
 
Further, in the microparticles prepared with PLGA, the initial burst is followed by 
a slow and incomplete release of insulin (218). This may be due to denaturation of insulin 
in the acidic environment created by the degradation products of PLGA (218, 219). This 
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denaturation of insulin can be reduced by incorporation of some basic excipients like 
sodium bicarbonate (113, 218),). Incomplete release of insulin from such systems is a 
major concern and may be a potential hazard and safety issue (218, 219). 
 
Implants are solid systems in form of tablets, rods, wafers, discs or films (113). 
These implants can be administered using a minor surgery or a trocar device. These 
implant systems may be biodegradable or non-biodegradable. In the case of non-
biodegradable systems, the removal of the system is necessary after depletion of the drug 
or after completion of the therapy. However, the biodegradable systems will degrade with 
time and fragment into water soluble products, which dissolve in interstitial fluid and 
goes away from the implant site (113). 
 
Different kind of implantable systems have been investigated by various groups to 
achieve an extended release of insulin (224). Ethylene–vinyl acetate copolymers (EVAc) 
have been used to make discs of insulin implants. These systems could reduce the blood 
glucose concentrations in diabetic rats from 30 to 105 days, depending on the 
formulations (224-228). However, in some of these systems, only a part of the loaded 
insulin could be released. Furthermore, the removal of the system after completion of the 
release was mandatory. Implants of insulin made up of cholesterol, palmitic acid, 
chitosan and gellan gum have also been studied in animals (226, 228-230). PLGA and 
PLA biodegradable implants have also been investigated by various groups (231, 232). 
 
1.5.4 Insulin pumps 
 
Insulin pumps are also known as continuous subcutaneous insulin infusion (CSII). 
Insulin pumps were first devised by Dr. Arnold Kadish in 1960 (233-235). Relative to the 
initial pumps, the modern pumps are smaller in size and called as micropumps. These 
micropumps consist of insulin reservoir, which is a replaceable cartridge, a catheter with 
tubing, and a micropump. To perform, the catheter of the pump is inserted 
subcutaneously and connected to reservoir through the tubing. The micropump controls 
the release of insulin from the reservoir. The efficient use of insulin pumps requires 
frequent blood glucose monitoring, and accordingly, adjustment of the rate of insulin 
release from the pumps. Since it can cover both basal and bolus needs of insulin, better 
glycemic control have been reported with these kind of pumps effectively. However, 
stability of insulin in the reservoir, patient compliance and cost of these pumps are certain 
issues that are affecting the acceptability of these pumps (113). 
 
1.5.5 Insulin gels 
 
Gels are colloid systems consisting of a dispersed phase, which is dispersed in a 
medium resulting in a semisolid form. The gel used as drug delivery systems consists of a 
drug, a polymer and a solvent. The drug can be suspended or dissolved in the solvent, 
depending on the solubility of the drug. 
 
Gels have been widely used for delivery of drugs via topical route. However, a 
few parenteral gel formulations like Eligard® and Atridox® have been marketed in the 
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USA. Both of these gels use the Atirgel® technology. The Atirgel® technology combines 
a biodegradable polymer, PLGA with a biocompatible solvent, NMP. The drug can be 
dispersed in polymer solution as a suspension or dissolved as a solution. The formulation, 
upon subcutaneous injection, forms a depot at the site of injection, and releases the drug 
for a prolonged period of time. A similar formulation, Alzamer®, has been developed by 
Alza Corporation using either ethyl benzoate or benzyl benzoate as the solvent. However, 
these systems suffer from initial burst, which must be controlled for successful delivery 
of insulin (113). 
 
Barichello et al. reported the use of Pluronic (PF 120) gel for delivery of insulin. 
However, these insulin gels could only maintain low blood glucose concentrations for up 
to 12 hours (113, 177, 236). 
 
Caliceti et al. reported preparation of hydrogels which change properties with 
change of environment such as temperature or pH. These gels could lower the blood 
glucose concentrations in diabetic rats after 2 hours after injection and maintained the 
effect for up to 100 hours. Kim et al.s reported the use of PLGA-PEG-PLGA polymer 
based gels (Relgel®) for preparation of insulin formulations (237). The gels are liquid at 
room temperature, but undergo a sol gel transformation at 37° C. Hence, an insulin 
containing solution of these gels when injected subcutaneously transforms to a solid and 
forms a depot, from which insulin can leach out for extended period of time. These 
formulations, upon subcutaneous injection in rats, could maintain low blood glucose 
concentrations for two weeks. Chen et al. made similar gels, but added zinc carbonate to 
them. The gel loaded with insulin Ultralente with zinc carbonate could keep the blood 
glucose concentrations in the normal range for 10 days in ZDF type 2 diabetic rats (113). 
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CHAPTER 2. PROLONGED EFFECT OF INSULIN IN PRESENCE OF WATER 
SOLUBLE AND WATER INSOLUBLE SOLUBLE ZINC SALTS 
 
 
2.1 Introduction 
 
Insulin is a metabolic hormone synthesized, stored and secreted from beta cells of 
pancreas. In beta cells of pancreas insulin is stored as granules consisting of insulin 
hexamers. These hexamers are composed of six units of insulin loosely connected by 
hydrophobic forces and further stabilized by presence of zinc ions (238). 
 
In 1937, Scott and Fisher used zinc for the first time in insulin formulations to 
stabilize protamine zinc insulin formulation (31, 34). In 1951, Hallas-Moller et al. came 
up with an idea of Lente insulins. Semilente was a suspension of amorphous modification 
of insulin and zinc, and had somewhat of a longer duration of action than the normal 
insulin. Ultralente was a crystalline modification of insulin (insulin crystallized in acetate 
buffer) with a longer duration of action similar to protamine zinc insulin formulation (35-
40, 82, 87, 239). 
 
Insulin interacts with zinc ions to form hexamers, and the hexamers get further 
stabilized in the presence of zinc. When these hexamers are injected subcutaneously, 
because of their inability to cross the capillary barriers, they form a depot at the site of 
injection. To get absorbed into the blood stream, these hexamers have to dissociate first 
into dimers and then to monomers. When these hexamers are injected subcutaneously, 
because of their inability to cross the capillary barriers, they form a depot at the site of 
injection. To get absorbed into the blood stream, these hexamers have to dissociate first 
into dimers and then to monomers. This leads to delayed and extended effect of insulin 
(68, 124, 238, 240). 
 
A novel injectable biodegradable gel system for controlled release drug delivery 
has been designed and characterized in our laboratory. It consists of a biodegradable 
polymer, PLGA, biocompatible plasticizer(s) and an active pharmaceutical ingredient 
(API). To date, several molecules, including antibiotics, opiate analgesics and narcotic 
antagonists, have been successfully incorporated into the gel system, and controlled 
release of the aforementioned APIs have been achieved in our laboratory. 
 
The long term aim of this study was to develop an injectable biodegradable gel 
system which can be used to control the release of insulin for one week or longer, after a 
single subcutaneous injection in type-2 diabetic ZDF rats. 
 
The objective of this part of the study was to investigate the effect of different 
water-soluble and water-insoluble zinc salts on blood glucose lowering effect of insulin 
in type-2 diabetic ZDF rats. 
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2.2 Materials and methods 
 
2.2.1 Materials 
 
Insulin (RHI) powder (26.9 IU/mg containing 0.4% zinc) was purchased from 
Diosynth France S.A. (Usine St. Charles, France) and Humulin® U (Ultralente insulin, 
10 mL) (Elli Lilly and Company, Indianapolis, IN) was purchased from Cardinal Health. 
The HPLC analysis of insulin was performed on a Shimadzu HPLC system (Shimadzu 
Scientific Instruments, Inc., Columbia, MD). The primary column was a 250 x 4.6 mm 
Alltech Macrosphere RP 300 C18 5 μm column and the guard column (Alltech, 
Deerfield, IL) was 7.5 x 4.6 mm, packed with same material as the primary column. 
HPLC grade Acetonitrile (ACN), trifloroacetic acid (TFA) and distilled water were used 
for preparing the mobile phase. Male ZDF (fa/fa) rats (Charles River Laboratories, Inc., 
Wilmington, MA) weighing 300-400 grams were used for the in vivo studies. Blood 
glucose was measured using Bayer Ascensia® Breeze blood glucose meter (Bayer 
Corporation, Elkhart, IN). The pH of the formulations was determined using pH meter 
(Model IQ 240, IQ Scientific Instruments, Inc., San Diego CA). 
 
2.2.2 Methods 
 
2.2.2.1 Preparation of the insulin and zinc suspensions. An appropriate quantity 
of insulin (RHI) powder was suspended in normal saline to make 40 IU/ml suspensions. 
Tables 2-1-2-4 shows the composition of insulin formulations containing varying 
concentrations of water-soluble (zinc sulfate or zinc chloride) and water-insoluble (zinc 
carbonate or zinc oxide) zinc salts. The ingredients were weighed into a 7-mL glass 
scintillation vial and water was added to bring the final weight to approximately 3 grams. 
An appropriate quantity of sodium chloride was added to each formulation to make the 
solution isotonic before adding insulin. Humulin® U suspension (100 IU/ml) was used as 
is. 
 
2.2.2.2 High pressure liquid chromatography method of insulin. The HPLC 
analysis of RHI was performed using a Shimadzu HPLC system (Shimadzu Scientific 
Instruments, Inc., Columbia, MD) consisting of an SCL-10A vp system controller, a LC-
10 AD vp pump, a DGU-14A degasser, an SIL-10 AD vp autoinjector with a cooling 
system, a CTO-10A vp column oven, an SPD-10 AD vp photo-diode array (PDA) 
detector and a computer loaded with the Shimadzu Class-VP 7.2 software. The primary 
column was a 250 x 4.6 mm Altech Macrosphere RP 300 C18 5 μm column and the 
guard column was 7.5 x 4.6 mm, packed with same material as the primary column. 
 
A gradient elution method was used for analyzing the insulin. Mobile phase A 
was 0.15% v/v trifluoroacetic acid (TFA) in water and mobile phase B was 0.13% v/v 
TFA in 95% v/v acetonitrile in water. Mobile phases were filtered through a 
Whatmann0.45 μm nylon membrane (Whatmann International Ltd, Maidstone, England) 
and degassed in an ultrasonicator (Model FS60, Fisher Scientific, Fair Lawn, NJ) for 10 
minutes before pumping it through the HPLC system. 
 25 
Table 2-1 Composition of insulin formulations containing zinc sulfate 
 
 
 
Formulation
# 
Insulin 
(mg) 
ZnSO4 
(mg) 
NaCl 
(mg) 
Adjust total 
weight with 
H2O(g) 
Amount of 
zinc in the 
formulation 
(mg/g) 
Molar 
ratio of 
insulin to 
zinc 
OA-2-1 4.56 - 27.00 3.00 - - 
OA-2-2 4.58 3.15 26.52 3.00 0.24 1:14 
OA-2-3 4.53 6.33 26.04 3.00 0.48 1:28 
OA-2-4 4.49 12.66 25.14 3.00 0.96 1:56 
OA-2-5 4.50 25.35 23.19 3.00 1.92 1:112 
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Table 2-2 Composition of insulin formulations containing zinc chloride 
 
 
 
Formulation
# 
Insulin 
(mg) 
ZnCl2 
(mg) 
NaCl 
(mg) 
Adjust total 
weight with 
H2O (g) 
Amount of 
zinc in the 
formulation 
(mg/g) 
Molar 
ratio of 
insulin  
to zinc 
OA-2-6 4.61 1.5 26.07 3.00 0.24 1:14 
OA-2-7 4.51 3.0 25.14 3.00 0.48 1:28 
OA-2-8 4.62 6.0 23.28 3.00 0.96 1:56 
OA-2-9 4.59 12.0 19.56 3.00 1.92 1:112 
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Table 2-3 Composition of insulin formulations containing zinc carbonate 
 
 
Formulation
# 
Insulin 
(mg) 
Zn CO3 
(mg) 
NaCl 
(mg) 
Adjust total 
weight with 
H2O (g) 
Amount of 
zinc in the 
formulation 
(mg/g) 
Molar 
ratio of 
Insulin 
to zinc 
OA-2-10 4.61 4.82 27.0 3.00 0.96 1:56 
OA-2-11 4.61 9.71 27.0 3.00 1.92 1:112 
OA-2-12 4.55 30 27.0 3.00 5.98 1:349 
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Table 2-4 Composition of insulin formulations containing zinc oxide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation
# 
Insulin 
(mg) 
ZnO 
(mg) 
NaCl 
(mg) 
Adjust total 
weight with 
H2O (g) 
Amount of 
zinc in the 
formulation 
(mg/g) 
Molar 
ratio of 
insulin 
to zinc 
OA-2-13 4.39 0.890 27.0 3.00 0.24 1:14 
OA-2-14 4.60 1.79 27.0 3.00 0.48 1:28 
OA-2-15 4.64 3.58 27.0 3.00 0.96 1:56 
OA-2-16 4.44 7.16 27.0 3.00 1.92 1:112 
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The initial mobile phase composition of 70% solvent A and 30% solvent B was 
maintained at a flow rate of 1 mL/min for 2 minutes. Between 2 and 16 minutes, the 
percentage of solvent B was increased linearly to 50%. These conditions were maintained 
for 3 minutes from 16 to 19 minutes. Between 19 and 24 minutes, the percentage of 
solvent B was decreased linearly to 30%. The mobile phase was pumped at a flow rate of 
1 mL/min. The injection volume of each sample, including the insulin standards, insulin 
controls, insulin samples (unknown concentration) and blank samples (0.01N HCl) 
without insulin was 50 μL. The temperature of the HPLC column was maintained at 30°C 
by using a column oven. The primary detection wavelength of insulin was set to 285 nm. 
 
2.2.2.3 Preparation of standard, control and sample solutions. The standard 
solutions and controls of insulin were prepared from recombinant human insulin. 
Approximately 10 or 25 mg of insulin was weighed accurately using an analytical 
balance and transferred to a clean dry 10 or 25 mL volumetric flask. Either 1 mL or 2.5 
mL of 0.01 N hydrochloric acid was added into the flask and the flask was swirled gently 
to dissolve the insulin powder. Isotonic phosphate buffered saline (PBS, pH 7.4) was 
used to make up the volume. The resultant solution contained approximately 1 mg/mL of 
insulin (working stock solution). Standard solutions were prepared from working stock 
solution by transferring the different amounts of working stock solution to five 10 mL 
volumetric flasks and making up the volume with PBS. The final insulin standard 
solutions contained 5, 10, 25, 50, 75, 100, 125, and 150 μg/mL of insulin, respectively. 
 
The insulin controls were also prepared from the working stock solution. These 
controls were always prepared and dispersed into small aliquots. Each aliquot was stored 
in a 1 mL HPLC vial and sealed by Parafilm. The controls were frozen at –20°C and one 
vial was thawed before the analysis. Depending on the approximate concentration of the 
insulin samples in each batch of analysis, one or two insulin controls were prepared 
accordingly. 
 
2.2.2.4 Process of chromatographic.data. After each HPLC injection, the 
software generated the chromatograph of the sample and integrated the peak area of 
insulin. The peak area of the standard solutions was then plotted against the concentration 
of insulin. 
 
2.2.2.5 Pharmacodynamic studies of insulin in ZDF rats. Pharmacodynamics of 
subcutaneously administered Humulin® U (Ultralente insulin, 10 mL) (Elli Lilly and 
Company, Indianapolis, IN) and insulin (Diosynth, Inc., Bensenville, IL) with and 
without varying concentrations of water-soluble and water-insoluble zinc salts was 
investigated in ZDF rats at a dose of 10 IU/kg. 
 
ZDF rats were randomly divided into groups of 4 to 6 animals per group. Each rat 
was anesthetized by isoflurane (Halocarbon Product Corporation, River Edge, NJ) using 
a SurgiVet/Anesco ventilator (Waukesha, WI) prior to handling the animals for injecting 
the insulin dosage forms and glucose measurement. Body weight of each animal was then 
recorded to determine the dose of the insulin suspensions to be injected. Blood glucose 
concentrations of each animal was measured before injecting insulin, using the 
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Ascensia™ Breeze™ glucose monitoring system (Bayer Corporation, Elkhart, IN). Each 
group received one dose of a particular form of insulin formulation. An appropriate dose 
of insulin was injected subcutaneously on the dorsal neck of each rat using a ½ mL 
Becton Dickinson Lo-Dose™ U-100 insulin syringe with a permanently attached 28 
gauge needle (0.5 inch in length) (Franklin Lakes, NJ). After injection, the rats were 
returned to the cages and allowed to recover from anesthesia. At pre-determined time 
intervals, the rats were anesthetized by the abovementioned method and blood glucose 
concentrations of the rats were measured. Blood glucose monitoring was stopped when 
the blood glucose concentrations reached their normally high concentrations. 
 
2.2.2.6 In vitro studies. Tables 2-1-2-4 lists amounts of ingredients used to 
prepare various RHI formulations with and without zinc salts. After 16 hours at room 
temperature, the pH of these formulations was determined using a calibrated pH meter. 
The formulations were then centrifuged (Eppendorf Centrifuge 5415 C) and the 
supernatant were collected into HPLC vials. Insulin concentrations were determined in 
the supernatant using a HPLC method as specified before. 
 
2.2.2.7 In vitro dissolution of insulin from insulin formulations with varying 
concentrations of zinc sulfate. The dissolution rate of RHI with and without zinc sulfate 
was studied using a dialysis method. Dialysis was conducted using the DispoDialyzer® 
ready-to-use tubes (500 μL capacity) purchased from Spectrum Laboratories (Rancho 
Dominguez, CA). The DispoDialyzer® tubes were made from cellulose ester, having a 
molecular weight cut-off of 50,000. The dialysis medium was isotonic PBS at pH 7.4. 
 
Before using, the DispoDialyzer® tubes were rinsed with the dialysis media 
(PBS). The rinsed tubes were then kept, submerged in the dialysis media for 30 minutes 
prior to use. 
 
An appropriate amount of insulin was suspended in PBS such that the 
concentration of insulin in the suspension was approximately 5 mg/mL (Table 2-4). In 
another set of samples, regular human insulin formulations with varying concentrations 
of zinc sulfate were prepared and used. Each formulation (0.5 mL) was then transferred 
to a DispoDialyzer® tube. Each DispoDialyzer® filled with insulin formulation was then 
placed into a 50 mL glass centrifuge tube, containing 25 mL of dialysis media.The 
DispoDialyzer® tube floated upright in the media. The centrifuge tube was capped, 
shaken at 100 rpm in an orbital shaker at room temperature. 
 
At pre-determined time intervals, the centrifuge tubes were removed from the 
shaker and 1 mL of dialysis media was withdrawn from each tube. The concentration of 
insulin in the media was determined by the HPLC method. The rest of the dialysis media 
in each centrifuge tube was dumped and 25 mL of fresh media was refilled. The tubes 
were then returned to the shaker and shaking was continued. The cumulative percentage 
of insulin dissolved from each suspension was plotted as a function of time. 
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2.3 Results and discussion 
 
2.3.1 Pharmacodynamic studies of insulin in ZDF rats 
 
Figure 2-1 shows the effect insulin on blood glucose concentrations in ZDF rats 
after a subcutaneous injection of insulin and ultralente insulin. The blood glucose 
concentrations decreased from 535 mg/dL to 77 mg/dL within two hours after 
administering a subcutaneous injection of regular insulin. Normal blood glucose 
concentration (50 to 200 mg/dL) was maintained in the animals for approximately 2.5 
hours, and within 6 hours after injection, the blood glucose returned to its initial high 
concentrations of 535 mg/dL. Therefore, the total duration of insulin activity in the 
animals was less than 6 hours. The blood glucose concentrations decreased from 431 
mg/dL to 74 mg/dL within four hours after administering a subcutaneous injection of 
ultralente. Normal blood glucose (50 to 200 mg/dL) was maintained in the animals for 
approximately 7 hours, and within 14 hours after injection, the blood glucose 
concentrations returned to its initial high concentrations of 375 mg/dL. Therefore, the 
total duration of ultralente activity was less than 14 hours. 
 
Figure 2-2 compares the mean and standard deviations of blood glucose 
concentrations in ZDF rats after a subcutaneous injection of insulin with varying 
concentrations of zinc sulfate. It is evident from the figure that adding varying amounts 
of zinc from 0.24 to 1.92 mg (obtained from zinc sulfate) to the regular insulin increased 
the Tmax (time at the lowest blood glucose concentration) from 2 hours (Tmax for 
regular insulin without any zinc) to 8 hours for formulation with 0.24 mg of zinc and 16 
hours for formulation with 1.92 mg of zinc. The Emax (lowest blood glucose 
concentration) after a subcutaneous injection of RHI was 75 mg/dL. 
 
The decrease in blood glucose concentrations from approximately 500 mg/dL to 
approximately 110 mg/dL was observed after subcutaneous injections of RHI with 0.24 
or 0.48 mg of zinc (obtained from zinc chloride), respectively (Figure 2-3). Normal blood 
glucose concentrations (50 to 200 mg/dL) were maintained for approximately 6 hours in 
the animals, which were injected with both the formulations, and within 10-12 hours after 
injecting either formulation, the blood glucose returned to its initial high concentrations 
of approximately 500 mg/dL. 
 
The drop in blood glucose concentrations after subcutaneous injections of insulin 
with 0.24 or 0.48 mg of zinc obtained from zinc chloride or zinc sulfate was similar to the 
drop in blood glucose concentrations after a subcutaneous injection of ultralente in the 
animals. The Emax after a subcutaneous injections of ultralente (Figure 2-1) was 140 
mg/dL, whereas, the Emax values after subcutaneous injections of regular insulin with 
0.24 or 0.48 mg of zinc obtained from zinc chloride or zinc sulfate was approximately 
110 –160 mg/dL (Figures 2-2 and 2-3). The drop in blood glucose concentrations after 
subcutaneous injections of insulin with 0.96 or 1.92 mg of zinc obtained from zinc 
chloride or zinc sulfate was more gradual than that observed after an injection of insulin 
with either 0.24 or 0.48 mg of zinc obtained from zinc chloride or zinc sulfate. Moreover, 
the Tmax for regular insulin with 0.96 or 1.92 mg of zinc obtained from zinc chloride or 
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Figure 2-1 Blood glucose concentrations of ZDF rats after a single subcutaneous 
injection of insulin at a dose of 10 IU/kg (Mean ± SEM, n = 6) 
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Figure 2-2 Comparison of blood glucose concentrations in ZDF rats after a single 
subcutaneous injection of insulin with varying concentrations of zinc sulfate (Insulin 
dose-10 U/kg) (Mean ± SEM, n = 4) 
 
 
 
 
 
 
 
 34 
0
100
200
300
400
500
600
0 4 8 12 16 20 24 28 32 36
Time (hr)
B
lo
od
 g
lu
co
se
 c
on
c.
 (m
g/
dL
)
Control
RI-ZnCl(Zn-0.24)
RI-ZnCl(Zn-0.48)
RI-ZnCl(Zn-0.96)
RI-ZnCl(Zn-1.92)
 
 
Figure 2-3 Comparison of blood glucose concentrations in ZDF rats after a single 
subcutaneous injection of insulin with varying concentrations of zinc chloride (Insulin 
dose-10 U/kg) (Mean ± SEM, n = 4) 
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zinc sulfate was 12 or 16 hours, respectively (Figures 2-2 and 2-3). Hence, insulin release 
could be extended by varying concentrations of both the water soluble salts of zinc. 
Moreover, the effect of different concentrations of zinc obtained from two different water 
soluble salts on the Tmax and Emax were similar. However zinc chloride, due to its very 
hygroscopic nature, was not used further in these studies. 
 
Figure 2-4 and Figure 2-5 compare the mean and standard deviations of blood 
glucose concentrations in ZDF rats after a subcutaneous injection of insulin with varying 
concentrations of water-insoluble zinc salts. Figure 2-4 depicts the blood glucose 
concentrations after subcutaneous injection of insulin with different concentrations of 
zinc, obtained from zinc carbonate. It is evident from the Figure 2-4 that adding varying 
amounts of zinc from 0.96 to 1.92 mg (obtained from zinc carbonate) to the insulin 
increased the Tmax (time at the lowest blood glucose concentration) from 2 hours (Tmax 
for regular insulin without any zinc) to only approximately 4 hours for formulation with 
0.96 mg and 1.92 mg of zinc. However, the blood glucose concentrations reached back to 
high concentrations of 500 mg/dL within 8 hours. 
 
Figure 2-4 and Figure 2-5 compare the mean and standard deviations of blood 
glucose concentrations in ZDF rats after a subcutaneous injection of insulin with varying 
concentrations of water-insoluble zinc salts. Figure 2-4 depicts the blood glucose 
concentrations after subcutaneous injection of insulin with different concentrations of 
zinc, obtained from zinc carbonate. It is evident from the Figure 2-4 that adding varying 
amounts of zinc from 0.96 to 1.92 mg (obtained from zinc carbonate) to the insulin 
increased the Tmax (time at the lowest blood glucose concentration) from 2 hours (Tmax 
for regular insulin without any zinc) to only approximately 4 hours for formulation with 
0.96 mg and 1.92 mg of zinc. However, the blood glucose concentrations reached back to 
high concentrations of 500 mg/dL within 8 hours. 
 
Figure 2-4 and Figure 2-5 compare the mean and standard deviations of blood 
glucose concentrations in ZDF rats after a subcutaneous injection of insulin with varying 
concentrations of water-insoluble zinc salts. Figure 2-4 depicts the blood glucose 
concentrations after subcutaneous injection of insulin with different concentrations of 
zinc, obtained from zinc carbonate. It is evident from the Figure 2-4 that adding varying 
amounts of zinc from 0.96 to 1.92 mg (obtained from zinc carbonate) to the insulin 
increased the Tmax (time at the lowest blood glucose concentration) from 2 hours(Tmax 
for regular insulin without any zinc) to only approximately 4 hours for formulation with 
0.96 mg and 1.92 mg of zinc. However, the blood glucose concentrations reached back to 
high concentrations of 500 mg/dL within 8 hours. 
 
Therefore, there was not much difference in the blood glucose concentrations of 
ZDF rats after subcutaneous injections of formulations of insulin containing zinc 
carbonate at two different zinc concentrations of 0.96 to 1.92 mg (Figure 2-1). 
Furthermore, the total duration of action in the animals for these formulations was shorter 
than that of Ultralente. Figure 2-5 depicts the blood glucose concentrations after a 
subcutaneous injection of insulin with different concentrations of zinc obtained from zinc 
oxide (another water-insoluble zinc compound). It is clear from the Figure 2-5 that 
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Figure 2-4 Comparison of blood glucose concentrations in ZDF rats after 
subcutaneous injection of insulin, ultralente and insulin with varying concentrations of 
zinc carbonate (Insulin dose-10 U/kg) (Mean ± SEM, n = 4) 
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Figure 2-5 Comparison of blood glucose concentrations in ZDF rats after a single 
subcutaneous injection of insulin with varying concentrations of zinc oxide (Insulin dose-
10 U/kg) (Mean ± SEM, n = 4) 
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increasing the amount of zinc oxide in the suspension formulation of insulin does not 
prolong the blood glucose lowering effect of insulin. 
 
Figure 2-6 shows a comparison of blood glucose concentrations in ZDF rats after 
subcutaneous injections of RHI with water-insoluble zinc carbonate and zinc oxide, and 
water-soluble zinc sulfate and zinc chloride. (Insulin dose-10 U/kg). It is evident from 
Figure 2-6 that the blood glucose lowering effect of insulin and maintenance of low blood 
glucose concentrations for a prolonged period of time in the ZDF rats was more than for 
the formulations prepared with water-soluble zinc salts than those prepared with water-
insoluble salts. This could be due to complexation of zinc ions (obtained from the water-
soluble salts) with the insulin and formation of an insoluble zinc-insulin hexamers. The 
hexamers could have been further stabilized to form higher molecular weight associates 
in presence of excess free zinc ions (86). 
 
These high molecular weight insulin associates (72000-256,000 Dalton) and 
hexamers (36000 Dalton) cannot cross the capillary barrier, and can only reach the blood 
stream after dissociation to monomers (86). This explains the reason of slow and 
prolonged effect of insulin in presence of high concentration of water soluble-salts like 
zinc chloride and zinc sulfate. The water-insoluble zinc salts, on the other hand, could not 
dissolve in the aqueous medium and hence could not provide the zinc ions to complex 
with the insulin molecules. 
 
2.3.2 In vitro release of insulin from insulin formulations with varying 
concentrations of zinc sulfate 
 
To further investigate the effect of zinc on RHI formulations, in vitro release 
studies were performed on insulin formulations prepared with water soluble zinc sulfate. 
Figures 2-7 and 2-8 depict the percentage release of insulin from suspensions of insulin 
prepared without and with varying concentrations of zinc sulfate, respectively, across a 
semi permeable membrane (dialysis bags with a MWCO of 50,000). Figure 2-7 shows 
that approximately 100 percent of insulin was released within 12 hours through the 
semipermeable membrane from the RHI formulation without any additional zinc sulfate. 
However, as shown in Figure 2-8, the release of insulin from RHI formulations prepared 
with two different concentrations of zinc (0.24 and 0.48 mg/gram of formulation) 
obtained from zinc sulfate was only approximately three percent at 48 hour time point. 
Moreover, no insulin was released from these formulations until 4 hours, and no 
detectable quantity of insulin was observed from RHI formulations prepared with 0.96 
and 1.92 mg/g of zinc (obtained from zinc sulfate) until 48 hours. The contents of dialysis 
bags containing RHI formulations were studied after 48 hours of release study. 
 
Figure 2-9 depicts the percentage of insulin remaining in the dialysis bags after 
completion of the in vitro release study (i.e. 48 hours), with RHI formulations prepared 
with varying concentration of zinc. The results of the study also showed that after 48 
hours of in vitro release study, approximately 3 percent of insulin was remaining inside 
the dialysis bags containing insulin formulations without any zinc.However, in the case 
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Figure 2-6 Comparison of blood glucose concentrations in ZDF rats after a single 
subcutaneous injection of insulin with water-soluble and water-insoluble zinc salts 
(Insulin dose-10 U/kg) (Mean ± SEM, n = 4) 
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Figure 2-7 Comparision of in vitro insulin release from insulin suspension 
formulations with and without zinc sulfate 
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Figure 2-8 Comparision of in vitro insulin release from insulin suspension 
formulations with zinc sulfate 
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Figure 2-9 Percentage of insulin remaining in the dialysis bags after completion of in 
vitro release study of insulin formulations with varying concentrations of zinc 
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of insulin formulations prepared with varying concentrations of zinc sulfate, settled 
insulin powder could be seen at the bottom of the dialysis bags.Quantitation of insulin 
concentration in these dialysis bags showed that approximately 88 to 96 percentage of 
insulin was still present inside the dialysis bags even after 48 hours. 
 
This further confirmed that fact that insulin forms hexamers and other complex 
associates of high molecular weight, which could not cross the dialysis bag with a 
MWCO of 50,000. To see the effect of pH on the concentration of insulin in the 
supernatant, insulin formulations with 0.24 mg of zinc/g of formulation (similar to 
Formulation OA-2-2) and without zinc (similar to Formulation OA-2-1) were prepared at 
different pH values of approximately 2.0, 3.0, 4.0, 5.0, and 5.6. Figure 2-10 shows the 
concentration of RHI in the supernatant obtained from these formulations at different pH 
values. It is clear from the figure that, as the pH decreased from 5.6 to 4.0, the amount of 
insulin dissolved in the supernatant increased from approximately 50 μg/mL to 1000 
μg/mL. As the pH decreased further to pH 2.0, the amount of insulin dissolved in the 
supernatant increased up to 1500 μg/mL, i.e. insulin dissolved completely at pH 2.0. This 
is in agreement with the prior findings that insulin dissolves at lower pH values (238, 
241). 
 
Figure 2-10 also shows the concentration of insulin in the supernatant in 
formulations prepared with 0.24 mg of zinc/ gram of formulation (similar to Formulation 
OA-2-2) at different pH values of approximately 2.0, 3.0, 4.0, 5.0, and 5.6. It is evident 
from the figure that the concentration of insulin in the supernatant in the presence of zinc 
was approximately 40 μg/mL and 100 μg/mL at pH 5.0 and 4.0, respectively. These 
insulin concentrations are considerably less than the insulin concentrations 
(approximately 400 μg/mL and 100 μg/mL) in the supernatant of the insulin formulations 
without zinc, at the similar pH values of 5.0 and 4.0. This may be because of interaction 
of insulin with zinc, leading to the formation and precipitation of insulin hexamers out of 
the solution. However at pH 3.0 and 2.0, the insulin concentrations in the supernatant of 
both the formulations prepared with and without zinc were similar. This also proves that 
insulin does not interacts with zinc at lower pH values (86). 
 
Figure 2-11 shows the pH and concentration of insulin in the supernatant obtained 
from formulations of insulin with varying concentrations zinc sulfate. The pH of insulin 
formulation without any additional zinc sulfate was approximately 5.6. As zinc sulfate 
was added to this insulin formulation, the pH decreased from 5.6 to approximately 5.05. 
With further addition of zinc sulfate, the pH decreased up to 4.85. The isoelectric point of 
insulin is 5.4 (238). Since insulin is more soluble in the acidic medium, as the pH went 
down towards the more acidic pH, i.e. away from the isoelectric point of insulin, more 
insulin dissolved in the medium. However, when these insulin formulations with varying 
concentrations of zinc sulfate were centrifuged and concentrations of insulin were 
determined in the supernatant, an opposite trend was observed. 
 
Figure 2-11 also shows the concentration of insulin in the supernatant obtained 
from formulations of insulin prepared with varying concentrations zinc sulfate. As shown 
in Figure 2-11, as the zinc sulfate concentration increased in the formulations, the pH of 
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Figure 2-10 Concentrations of insulin in the supernatant obtained from formulations of 
insulin alone or insulin with zinc sulfate (0.24mg/mL) at different pH values 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
400
800
1200
1600
5.6 5 4 3 2
pH
C
on
ce
nt
ra
tio
n
(m
cg
/m
L)
RHI
RHI+ Zinc
 45 
RHI + No Zinc
(pH 5.57)
RHI + Zinc (0.24)
(pH 5.06)
RHI+Zinc(0.48)
(pH 4.96)
RHI+Zinc(0.96)
(pH 4.91)
RHI+Zinc(1.92)
(pH 4.85)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
-
C
o
n
c
e
n
tr
a
ti
o
n
 (
m
c
g
/m
L
)
RHI+No Zinc(pH 5.57) RHI+Zinc(0.24)(pH 5.06) RHI+Zinc(0.48)(pH 4.96)
RHI+Zinc(0.96)(pH 4.91) RHI+Zinc(1.92)(pH 4.86)  
 
Figure 2-11 pH and concentration of insulin in the supernatant obtained from 
formulations of insulin (RHI) with varying concentrations zinc sulfate 
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the formulation decreased from 5.57 to 4.85. However, as the zinc sulfate concentration 
increased in the formulations, the insulin concentration in the supernatant of the 
formulation also decreased from approximately 50 μg/mL to 5 μg/mL.This approximately 
10 fold decrease, in insulin concentration in the supernatant of the formulations may be 
due to an increase in the zinc ions in the formulations. 
 
To investigate this phenomenon further, four different formulations were prepared 
at the final pH of approximately 5.05, 4.95, 4.90 and 4.85. These final pH values were 
selected based on the pH values of formulations of insulin with varying concentrations 
zinc sulfate. The insulin concentration was determined in the supernatant of these 
formulations after similar treatment as of formulations of insulin with varying 
concentrations zinc sulfate. As indicated in Figure 2-12 the insulin concentration, in the 
supernatant of the insulin formulations was much lower in the presence of zinc at similar 
pH values. 
 
Figure 2-13 depicts the possible explanation of this finding. In the formulations of 
RHI with varying concentrations zinc sulfate, insulin was in suspension and zinc ions 
were in solution. With the addition of more zinc sulfate, the pH of the medium decreased 
and the medium became acidic. Since the solubility of insulin is more at the acidic pH, 
more insulin solublized at lower pH and hence was available to form hexamers in the 
presence of excess of zinc ions. As more hexamers and loose associates of hexamers 
were formed, they precipitated out of the solution thus resulting in a decrease in the net 
insulin concentration in the supernatant. When these insulin formulations with varying 
concentrations of zinc and containing hexamers were administered to the ZDF rats, the 
insulin hexamers and loose associates could not cross the capillary barrier; and thus 
formed a depot at the site of the injection. This depot formation may be the reason for the 
prolonged in vivo effect of the insulin formulations prepared with varying concentrations 
zinc sulfate, after subcutaneous injections in the ZDF type 2 diabetic rats. 
 
 
2.4 Conclusions 
 
The blood glucose lowering effect of insulin could be extended by varying 
concentrations of both the water-soluble salts of zinc. However, the blood glucose 
lowering effect of insulin and maintenance of low blood glucose concentrations for a 
prolonged period of time in the ZDF rats was more than for the formulations prepared 
with water-soluble zinc salts than those prepared with water-insoluble salts. This could be 
due to complexation of zinc ions (obtained from the water-soluble salts) with the insulin 
and formation of an insoluble zinc-insulin hexamers. 
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Figure 2-12 Concentration of insulin (RHI) in the supernatant obtained from 
formulations of insulin alone at different pH, or formulations of insulin with varying 
concentrations zinc sulfate 
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Figure 2-13 Possible mechanism of extended in vivo effect of formulations of insulin 
with varying concentrations zinc sulfate 
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CHAPTER 3. CONTROLLED RELEASE OF INSULIN FROM NOVEL 
BIODEGRADABLE INJECTABLE GELS 
 
 
3.1 Introduction 
 
Diabetes mellitus is a chronic disorder characterized by hyperglycemia. It is 
recognized as a worldwide epidemic by the WHO. The disease may be further classified 
as type-1 and type-2. Type-1 diabetes mellitus patients can survive only by regular 
administration of insulin, whereas type-2 diabetes mellitus patients can be treated with 
oral hypoglycemic agents and some other new classes of anti diabetic drugs. However, 
type-2 patients may also need insulin therapy at some point. Hence, insulin is pivotal in 
treating diabetes (242-244). 
 
For successful insulin therapy, daily subcutaneous injections of insulin are 
required. Subcutaneous insulin has been satisfactory in terms of efficacy in majority of 
cases. However the use of these subcutaneous injections may cause hyperinsulinemia 
which may lead to hypoglycemia and diabetic micro and macro angiopathy. Further, 
these subcutaneous injections of insulin are also associated with pain, inconvenience, 
physiological stress, high cost, difficulty in handling insulin, localized insulin deposition 
leading to local hypertrophy and fat deposition at site of injection. Most insulin regimens 
require multiple daily injections which are associated with poor patient compliance. 
Reduction in number of insulin injections can significantly improve efficacy of insulin 
therapy (6, 18). 
 
Insulin interacts with zinc ions to form hexamers. In the presence of zinc, these 
hexamers further get stabilized. When these hexamers are injected via subcutaneous 
route, they form a depot at the site of injection because of their inability to cross the 
capillary barriers. To get absorbed into the blood stream, these hexamers have to 
dissociate first into dimers and then to monomers. This leads to a delayed and extended 
effect of insulin in presence of zinc (124, 238, 245). 
 
Various controlled release forms of insulin like microspheres, implants, gels, 
liposomes, and stereocomplexes have been investigated as extended release dosage forms 
of insulin. A novel injectable biodegradable gel system for controlled release drug 
delivery has been designed and characterized in our laboratory. It consists of a 
biodegradable polymer, PLGA, biocompatible plasticizer(s) and an active pharmaceutical 
ingredient (API). Chen et al. reported use of these gel systems for extended delivery of 
insulin for approximately one week (113). Chen et al. used ultralente crystals extracted 
from a commercial formulation (113). They also showed that adding a water-insoluble 
salt of zinc, zinc carbonate, further slowed down the release profile from these gels. 
 
This work is continuation of the work done by Chen et al. and the aim of this 
study was to design insulin gel formulations, which could provide constant blood glucose 
lowering effect of the released insulin in diabetic rats for one week or longer, after a 
single subcutaneous injection. However in this part of study we intend to study the 
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incorporation of water-soluble salt, zinc sulfate, and its effect on prolongation of blood 
glucose lowering effect of regular human insulin, released from these gels. 
 
 
3.2 Materials and methods 
 
3.2.1 Materials 
 
Insulin (RHI) powder (26.9 IU/mg, 0.4% zinc) used in this study was purchased 
from Diosynth France S.A. (Usine St. Charles, France). The polylactic-co-glycolic acid 
(PLGA) used in this study was Medisorb® 5050 DL 1A (i.v. 0.09 dL/g). It was donated 
by Alkermers Inc. (Cambridge, MA). According to the manufacturer’s technical 
information, PLGA 5050 DL 1A has a degradation time of 1-2 weeks (246). This grade 
of PLGA was selected because it has the shortest degradation time. Zinc sulfate used in 
this study was of laboratory grade and was bought from Sigma Chemicals (St. Louis, 
MO). Acetyl triethyl citrate (ATEC) and triethyl citrate (TEC) used in this study were 
generous donations from Morflex Inc. (Greensboro, NC). Male ZDF (fa/fa) rats weighing 
300-400 grams used for the in vivo studies were received as donations from the Charles 
River Laboratories, Inc., (Wilmington, MA). Blood glucose was measured using Bayer 
Ascensia® Breeze blood glucose meter (Bayer Corporation, Elkhart, IN). 
 
3.2.2 Methods 
 
3.2.2.1 Preparation of insulin-zinc sulfate co-precipitates. An appropriate 
quantity of insulin (RHI) powder was suspended in normal saline to make insulin 
suspensions. Table 3-1 shows the composition of insulin formulations containing varying 
concentrations of zinc sulfate. The ingredients were weighed into a glass vial and water 
was added to bring the final weight to approximately 60 grams. Any lumps, if present, 
were broken using a stainless steel spatula. These formulations were kept at room 
temperature overnight (approximately 16 hours). The next day, the supernatant of the 
formulation was carefully removed and the precipitates were dried under vacuum at room 
temperature for 24 hours. The next day, the supernatant of the formulation was carefully 
removed and the precipitates were dried under vacuum at room temperature for 24 hours. 
The dried insulin-zinc sulfate co-precipitates were checked for any lumps, which if 
present were carefully triturated using a stainless steel spatula. Appropriate amounts of 
these insulin-zinc sulfate co-precipitates were loaded into the blank gel as shown in the 
Table 3-2 one day prior to subcutaneous administration to the ZDF rats. Zinc 
concentrations in the insulin-zinc precipitates were determined by atomic absorption 
spectrophotometer. 
 
3.2.2.2 Fabrication of the gels. The gel formulations were prepared in two steps: 
dissolution of polymer in the plasticizer(s) to obtain a blank gel and loading of insulin 
alone or insulin zinc sulfate co-precipitates or insulin and zinc sulfate separately into the 
blank gel. The polymer, PLGA was allowed to come to room temperature in vacuum 
desiccators after it was taken out of the freezer. 
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Table 3-1 Formulations of insulin suspensions 
 
 
Formulation 
# 
Insulin 
(mg) 
Zn SO4
(mg) 
NaCl 
(mg) 
Adjust total 
weight with 
H2O (g) 
Amount of 
zinc in the 
formulation 
(mg/g) 
Molar 
ratio of 
insulin 
to zinc 
OA-3-3 90 63 530 60 0.24 1:14 
OA-3-4 90 127 521 60 0.48 1:28 
OA-3-5 90 253 501 60 0.96 1:56 
OA-3-6 90 507 464 60 1.92 1:112 
 52 
Table 3-2 Formulation composition of PLGA gel containing insulin and zinc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation 
# 
ATEC 
(%) 
TEC 
(%) 
Insulin + 
ZnSO4 
co-
precipitate
(%) 
Polymer 
(%) 
Insulin + 
ZnSO4  
co- 
Precipitate  
of 
formulation 
Actual 
Ratio 
Insulin:
zinc 
OA-3-7 68.25 22.75 4 5 OA-3-3 1:14 
OA-3-8 68.25 22.75 4 5 OA-3-4 1:28 
OA-3-9 68.25 22.75 4 5 OA-3-5 1:56 
OA-3-10 68.25 22.75 4 5 OA-3-6 1:112 
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The desired amount of plasticizer(s) was weighed into the scintillation vial 
containing the polymer. A plastic screw cap with aluminum liner was used to seal the 
vial. The vial was then vortexed on a vortex mixer to disperse the polymer particles in the 
plasticizer(s). The vial was placed and in a Lab-Line orbital shaker (Model 3527, Lab-
line, Melrose Park, IL) maintained at 37°C and shaken at 150 rpm. It took 2 to 3 days for 
the polymer to completely dissolve. 
 
The resulting blank gel was stored in a vacuum desiccator at room temperature 
until further use (typically 1 to 2 days). For preparing insulin-loaded gel, a desired 
amount of blank gel was transferred to a new glass scintillation vial, and an appropriate 
amount of either pure insulin particles (Table 3-3) or insulin-zinc sulfate co-precipitates 
(Table 3-4) was accurately weighed and transferred into the blank gel. 
 
3.2.2.2 Preparation of physical mixtures of insulin and zinc sulfate. In the 
formulations containing insulin and zinc sulfate, the zinc sulfate was first passed through 
sieve number 400 (37.5 μm). An appropriate amount of the sieved zinc sulfate was 
weighed and mixed with insulin by the geometric dilution method. The resulting mixture 
of insulin and zinc sulfate was loaded into the blank gels. A stainless steel spatula was 
used to stir the mixture. Any visible agglomerates of insulin and/or zinc sulfate were 
broken using the spatula. Mixing was continued until a uniform mixture of insulin and 
zinc sulfate in the gel was produced. 
 
3.2.2.3 Pharmacodynamic studies of in ZDF rats. All the experimental procedures 
for the animal studies were approved by the University of Tennessee Health Science 
Center’s Animal Resources Advisory Committee (Protocol 1622). The ZDF rats (Charles 
River Laboratories, Wilmington, MA) were at least 16 weeks old and weighed 
approximately 300 to 400 g. Hyperglycemia (> 400 mg/dL) in the ZDF rats was 
confirmed by blood glucose measurements. 
 
The rats were group-housed (3 per cage) in the animal facility under a 12-hour 
light/dark cycle. They had access to food and water ad libitum throughout the studies. 
Before the animals were shipped from Charles River Laboratories, they were fed Purina 
diet #5008 until they fully developed diabetes (12 weeks old). The animals were on 
regular laboratory rodent food in our facility. The rats were acclimated to the 
environment for at least three days before they were used in the studies. 
 
On each day of the study, the ZDF rats were transferred to the procedure room. 
The rats were randomly divided into groups, with 4 to 6 animals per group. Each group, 
except the control group, received one dose of an insulin formulation. The control group 
did not receive any insulin injection. Before injection, each rat was placed in an induction 
chamber and anesthetized by isoflurane (Halocarbon Product Corporation, River Edge, 
NJ) using a SurgiVet/Anesco ventilator (Waukesha, WI). Body weight of the animal was 
recorded to determine the volume of the insulin formulation to be injected. Blood glucose 
was measured using Bayer Ascensia® DEX® 2 or Ascensia Breeze blood glucose meter 
(Bayer Corporation, Elkhart, IN). The dose of insulin formulation was injected 
subcutaneously at the dorsal neck of the rat using a 1 mL syringe with an attached 23 
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Table 3-3 Formulation composition of PLGA gel containing insulin and zinc sulfate 
physical mixtures 
 
 
 
Formulation 
# 
ATEC 
(%) 
TEC 
(%) 
Insulin 
(%) 
Polymer
(%) 
ZnSO4 
(%) 
Actual 
ratio 
insulin: 
zinc 
OA-3-11 68.25 22.75 4 5 1 1:14 
OA-3-12 68.25 22.75 4 5 2 1:28 
OA-3-13 68.25 22.75 4 5 2.8 1:14 
OA-3-14 68.25 22.75 4 5 5.6 1:28 
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Table 3-4 Zinc contents in insulin-zinc co-precipitates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Precipitate of 
Formulation 
# 
Formulation 
composition of 
precipitate 
(mg/g) 
Amount zinc 
(µm)/insulin (mg) 
Ratio  
insulin : zinc
OA-3-3 RHI-Zn-0.24 7.78 ± 0.69 06:04.1 
OA-3-4 RHI-Zn-0.48 10.88 ± 0.96 06:05.1 
OA-3-5 RHI-Zn-.96 13.77 ± 2.77 06:07.2 
OA-3-6 RHI-Zn-1.92 11.67 ± 3.82 06:06.1 
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gauge 1 inch needle (Franklin Lakes, NJ). After injection, the rats were returned to the 
cages and allowed to recover from anesthesia. At pre-determined time intervals, the rats 
were anesthetized by aforementioned method and their blood glucose concentrations 
were measured. 
 
A plot of blood glucose concentrations versus time was generated from the data to 
describe the glucose lowering effect of insulin, from which information such as time of 
peak action and duration of action could be obtained. 
 
 
3.3 Results and discussion 
 
Pharmacodynamic studies of different gel formulations of insulin in ZDF rats: 
Two different gel formulations consisting of 5 and 10 % PLGA were made by suspending 
insulin particles in the blank gels (Table 3-5). These insulin formulations were 
administered subcutaneously to ZDF rats to evaluate the biological effect of insulin 
released from these formulations. Specifically, the blood glucose concentrations and body 
weights of the rats were measured at periodic time intervals following the subcutaneous 
injection. Figure 3-1 shows changes in blood glucose concentrations of ZDF rats after a 
subcutaneous injection of PLGA (5 and 10%) gel formulation loaded with 4% insulin 
(Formulations OA-3-1 and OA-3-2). It is evident from Figure 3-1 that the blood glucose 
concentrations decreased from approximately 554 + 29.4 mg/dL to 63 ± 10.6 mg/dL 
within 6 hours after a subcutaneous injection of Formulation OA-3-1 (5% PLGA) in the 
ZDF rats. The blood glucose concentrations were below 80 mg/dL in all the six rats, i.e. 
all the rats were hypoglycemic within six hours after injection. Further, the blood glucose 
concentrations of all the six rats were below 70 mg/dL within 12 hours after 
subcutaneous administration of the formulation. However, the blood glucose 
concentrations of all the six rats increased to normally high values of 443 + 55.7 mg/dL 
within 24 hour after subcutaneous administration of the formulation, and remained high 
thereafter. A similar blood glucose concentration profile was obtained after subcutaneous 
injection of formulation OA-3-2 (10% PLGA). The blood glucose concentrations 
decreased from approximately 452 + 27.38 mg/dL to 92.5 ± 4.9 mg/dL within 6 hours 
after a subcutaneous injection of the formulation. 
 
The blood glucose concentrations further declined to below 75 mg/dL after 12 
hours after administration of the formulation. As with 5 % PLGA formulation, the blood 
glucose concentrations of all of the six rats increased to normally high values of 331 + 
35.1 mg/dL, 24 hours after administration of the formulation and remained high 
thereafter. It is evident from these results that these insulin formulations consisting of 5 
and 10% PLGA release insulin at a very rapid rate, leading to hypoglycemia in all the 
rats. It is evident from these results that these insulin formulations consisting of 5 and 
10% PLGA release insulin at a very rapid rate, leading to hypoglycemia in all the rats. 
Further, the blood glucose concentrations could not be maintained at low concentrations 
(80 to 100 mg/dL) for a long period of time, and the all the rats were hyperglycemic 
within 24 hours after the subcutaneous injection of these formulations. 
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Table 3-5 Formulation composition of PLGA gel of insulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation 
# 
 
ATEC 
(%) 
TEC 
(%) 
Insulin 
(%) 
Polymer 
(%) 
 
OA-3-1 
 
68.25 
 
22.75 
 
4 
 
5 
 
OA-3-2 
 
 
68.25 
 
 
22.75 
 
 
4 
 
 
10 
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Figure 3-1 Changes in blood glucose concentrations of ZDF rats after a subcutaneous 
injection of PLGA (5% and 10%) gel formulations loaded with 4% insulin (Formulations 
OA-3-1 and OA-3-2) (Mean ± SEM, n = 5) 
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Figure 3-2 shows changes in the body weights of ZDF rats after a subcutaneous 
injection of the PLGA (5 and 10% ) gel formulation loaded with 4% insulin 
(Formulations OA-3-1 and OA-3-2). The body weights of these ZDF rats 24 hours after 
subcutaneous injection of the PLGA formulations (5 and 10%) were higher than before 
the injection of the formulations. However, the body weights came back to approximate 
initial values within 48 hours after the injection of these formulations. This 
pharmacodynamic effect shown by the changes of the body weights after the 
subcutaneous injection is similar to the pharmacodynamic effect of the changes in the 
blood glucose concentrations. This shows that these formulations (Formulations OA-3-1 
and OA-3-2) could not control the release of insulin for a prolonged period of time after a 
single subcutaneous injection in the ZDF rats, and the insulin effect lasted for less than 24 
hours. 
 
As shown in the previous study (Chapter-2) and reported by other groups, insulin 
zinc interaction can extend the in vivo duration of action of insulin (238). Further, as 
shown by Chen et al. (113) and Kim et al. (247), incorporation of water-insoluble zinc 
salt in a similar type of polymer based gels slowed down the insulin release and extended 
the in vivo duration of action of insulin. In this study, we purposed that incorporation of a 
water-soluble zinc salt, zinc sulfate, in these PLGA formulations of regular human insulin 
can prolong the blood glucose lowering effect of regular human insulin. 
 
The insulin-zinc co-precipitates (Formulations OA-3-3, OA-3-4, OA-3-5 and OA-
3-6) were loaded in 5% PLGA gels and four different formulations were obtained 
(Formulations OA-3-7, OA-3-8, OA-3-9 and OA-3-10). These formulations were injected 
subcutaneously in ZDF rats and change in blood glucose concentrations and body 
weights were monitored for a week. Figure 3-3 shows the changes in blood glucose 
concentrations of ZDF rats after a subcutaneous injection of 5% PLGA gel formulation 
loaded with 4% insulin alone (Formulation OA-3-1) or insulin-zinc sulfate co-precipitates 
(Formulations OA-3-7 and OA-3-8). It is evident from the figure that the blood glucose 
lowering effect of 5% PLGA formulation consisting of insulin alone (Formulation: OA-
3-1) lasted less than 24 hours. After a subcutaneous injection of 5% PLGA formulation 
(Formulation OA-3-7), consisting of insulin-zinc sulfate co-precipitates of Formulation 
OA-3-3 (0.24 mg of zinc /gram of formulation), the blood glucose concentrations. 
 
The blood glucose concentrations remained below 100 mg/dL until 24 hours 
before increasing to approximately 200mg/dL after 48 hours after the subcutaneous 
injection of the formulation. The blood glucose concentrations steadily increased above 
350 mg/dL and remained above this concentration thereafter. In the case of 5% PLGA 
formulation (Formulation OA-3-8), consisting of insulin-zinc co-precipitates of 
Formulation OA-3-4 (0.48 mg of zinc gram of formulation), the blood glucose 
concentrations decreased from approximately 426 + 15.9 mg/dL to 75 ± 17.3 mg/dL 
within 12 hours after the subcutaneous injection. The blood glucose concentrations 
remained below 150 mg/dL for up to 3 days before increasing to approximately 330 
mg/dL after 4 days after the subcutaneous injection of the formulation. The blood glucose 
concentrations increased steadily above 350 mg/dL and remained above this 
concentration thereafter. This shows that when the insulin-zinc co-precipitates were 
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Figure 3-2 Changes in body weights of ZDF rats after subcutaneous injections of 
PLGA (5 and 10%) gel formulations loaded with 4% insulin (Formulations OA-3-1 and 
OA-3-2) (Mean ± SEM, n = 5) 
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Figure 3-3 Changes in blood glucose concentrations of ZDF rats after subcutaneous 
injections of PLGA (5%) gel formulations loaded with 4% insulin alone (Formulation 
OA-3-1) or insulin-zinc co-precipitates (Formulations OA-3-7 and OA-3-8) (Mean ± 
SEM, n = 5) 
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loaded in the 5% PLGA gel formulations (Formulations OA-3-5 and OA-3-6) and 
injected subcutaneously in the ZDF rats, the blood glucose concentrations decreased 
slowly and remained at low concentrations (between 100 and 200 mg/dL) for a longer 
period of time. Addition of zinc also reduced the chances of occurrence of hypoglycemia 
in the ZDF rats after the subcutaneous injection of these PLGA formulations containing 
insulin. Further, with increase in the zinc, the in vivo effect of insulin was extended from 
1 day to up to 3 days. 
 
Figure 3-4 shows the changes in blood glucose concentrations of ZDF rats after a 
subcutaneous injection of 5% PLGA gel formulation loaded with 4% insulin alone 
(Formulation OA-3-1) or insulin-zinc co-precipitates (Formulations OA-3-9 and OA-3-
10). 
 
Figure 3-4 shows the changes in blood glucose concentrations of ZDF rats after a 
subcutaneous injection of 5% PLGA gel formulation loaded with 4% insulin alone 
(Formulation OA-3-1) or insulin-zinc co-precipitates (Formulations OA-3-9 and OA-3-
10). After subcutaneous injection of 5% PLGA formulation (Formulation OA-3-9), 
consisting of insulin-zinc co-precipitates of Formulation OA-3-5 (0.96 mg of zinc /gram 
of formulation), the blood glucose concentrations decreased from approximately 492 + 
29.3 mg/dL to 105 ± 19.2 mg/dL within 12 hours after the subcutaneous injection. The 
blood glucose concentrations remained below 150 mg/dL for up to 2 days before 
increasing to approximately 300 mg/dL after 3 days after the subcutaneous injection of 
the formulation. The blood glucose concentrations increased steadily above 350 mg/dL 
and remained above this concentration thereafter. In the case of 5% PLGA formulation 
(Formulation OA-3-10 ) consisting of insulin- zinc co-precipitates of Formulation 
(Formulation OA-3-6 with 1.92 mg of zinc /gram of formulation), the blood glucose 
concentrations decreased slowly from approximately 467+ 51.5 mg/dL to 99.8± 17.5 
mg/dL within 24 hours after the subcutaneous injection. The blood glucose 
concentrations remained below 175 mg/dL for up to 3 days before increasing to 
approximately 300 mg/dL after 4 days after the subcutaneous injection of the 
formulation. 
 
The blood glucose concentrations increased steadily above 350 mg/dL and 
remained above this concentration thereafter. This change in blood glucose 
concentrations shows that the effect of insulin does not last longer than 3 days after the 
subcutaneous injection of these 5% PLGA formulations containing insulin-zinc co-
precipitates. Further, there was an increase in the duration of blood glucose lowering 
effect of insulin from Formulation OA-3-8 (5% PLGA gel containing 4% insulin-zinc co-
precipitate with 0.48 mg of zinc/ gram of formulation) as compared to Formulation OA-
3-7 (5% PLGA gel containing 4% insulin-zinc co-precipitate with 0.24 mg zinc / gram of 
formulation) and Formulation OA-3-1 (5% PLGA gel containing 4% insulin). However, 
there was no further increase in the in vivo duration of insulin when 5% PLGA gel 
ormulations loaded with insulin-zinc co-precipitates having more zinc sulfate (obtained 
from Formulation OA-3-5 with 0.96 mg zinc/ gram of formulation and Formulation OA-
3-6 with with 1.92 mg zinc / gram of formulation), were subcutaneously injected in the 
rats. 
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Figure 3-4 Changes in blood glucose concentrations of ZDF rats after subcutaneous 
injections of PLGA (5%) gel formulations loaded with 4% insulin alone (Formulation 
OA-3-1) or insulin-zinc co-precipitates (Formulations OA-3-9 and OA-3-10) (Mean ± 
SEM, n = 5) 
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After subcutaneous injections of 5 and 10% PLGA formulations of insulin (Figure 
3-1) all the rats went to hypoglycemia within 6 hours. However, as the insulin-zinc co-
precipitates loaded gels were subcutaneously injected in rats, the number of rats going 
into hypoglycemia decreased substantially. The blood glucose concentrations also 
decreased slowly after the subcutaneous injection of the 5% PLGA formulations of 
insulin-zinc co-precipitates. 
 
Figure 3-5 shows the changes in the body weights of ZDF rats after a 
subcutaneous injections of 5% PLGA gel formulations loaded with 4% insulin-zinc co-
precipitates (Formulations OA-3-7, OA-3-8, OA-3-9 and OA-3-10). It is evident from the 
figure that the body weights of ZDF rats increased 24 hours after the subcutaneous 
injections. However, in the case of Formulation OA-3-7, a very rapid weight gain was 
observed on day 1, after which it slowly declined. In the case of other formulations, the 
body weights of ZDF rats increased on day 1 and remained steady for up to day 3 
followed by a slow decline after the subcutaneous injections. This change in body 
weights also showed that the effect of insulin does not last longer than 3 days after 
subcutaneous injection of these 5% PLGA formulations containing insulin-zinc co-
precipitates. Since the blood glucose lowering effect of these 5% PLGA formulations 
containing insulin-zinc co-precipitates could not be extended for more than three days, 
the actual zinc content of these insulin-zinc co-precipitates was determined using atomic 
absorption spectrophotometer. As shown in Table 3-5, the actual zinc content of these co-
precipitates was much lower. Two zinc ions are required to interact with six molecules of 
insulin to form a hexamer. These insulin-zinc co-precipitates have 4 to 7 zinc ions per six 
insulin molecules, which may be sufficient to transform all the insulin molecules into 
hexamers. Therefore, the initial blood glucose lowering effect was slow in formulations 
containing insulin-zinc co-precipitates. However, after subcutaneous injections, these co-
precipitates were exposed to interstitial fluid, which dissolved and quickly removed the 
zinc ions from the injection site. Furthermore, the zinc ions present in these co-
precipitates were not in excess to extend the effect of insulin for a long time. 
 
To increase the amount of zinc in the formulations, zinc sulfate was directly 
loaded in the PLGA gels. Figure 3-6 shows the change in blood glucose concentrations in 
ZDF rats after subcutaneous injections of insulin loaded in 5% PLGA gel formulations 
with different concentrations of zinc sulfate (Formulations OA-3-11 and OA-3-12 
containing 1 and 2% zinc sulfate, respectively). Formulation OA-3-1 prepared with 5% 
PLGA and having no zinc sulfate in it, showed a rapid decline in the blood glucose 
concentrations; reaching below 75 mg/dL in 6 hours. The blood glucose concentrations 
remained below 75 mg/dL for up to 12 hours, before climbing back to the normally high 
concentrations 350 mg/dL within 24 hours. 
 
Formulations OA-3-11 and OA-3-12 containing 1 and 2% of zinc sulfate 
respectively, were prepared with 5% PLGA. Formulation OA-3-11 (containing 1% zinc 
sulfate) showed a slow decline in the blood glucose concentrations, reaching below 200 
mg/dL in 12 hours and below 75 mg/dL in 24 hours. The blood glucose concentrations 
remained below 100 mg/dL for 3 days before slowly climbing up to 300 mg/dL 
concentrations at 5 days and remained above this concentration thereafter. 
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Figure 3-5 Changes in body weights of ZDF rats after subcutaneous injections of 
PLGA (5%) gel formulations loaded with 4% insulin-zinc co-precipitates (Formulations 
OA-3-7, OA-3-8, OA-3-9 and OA-3-10) (Mean ± SEM, n = 5) 
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Figure 3-6 Changes in blood glucose concentrations of ZDF rats after subcutaneous 
injections of insulin alone (Formulations OA-3-1) or physical mixtures of insulin (4%) 
and zinc sulfate (1 or 2%) loaded in PLGA (5%) gel formulations (Formulations OA-3-
11 and OA-3-12) (Mean ± SEM, n = 5) 
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Formulation OA-3-12 (containing 2% zinc sulfate) showed a similar pattern as 
that of Formulation OA-3-11. When the zinc sulfate increased in the formulation, the 
blood glucose concentrations declined below 100 mg/dL even more slowly in 24 hours. 
The blood glucose concentrations remained below 200 mg/dL for 4 days before slowly 
climbing up to 300 mg/dL concentrations at 5 days and remained above this 
concentration thereafter. Thus, with addition of zinc sulfate in the 5% PLGA 
formulations, the blood glucose concentrations decreased at a slower rate. However, even 
with addition of 2% zinc sulfate, the blood glucose concentrations remained below 200 
mg/dL only for 4 days. To investigate the effect of even higher concentrations of zinc 
sulfate, the amount of zinc sulfate was increased to 2.8 and 5.4% in the 5% PLGA gel 
formulations. Figure 3-7 shows the change in blood glucose concentrations in ZDF rats 
after subcutaneous injections of insulin loaded in 5% PLGA gels with higher 
concentrations of zinc sulfate (2.8 and 5.4%). Formulations OA-3-13 and OA-3-14 
containing 2.8 and 5.6% of zinc sulfate, respectively were prepared with 5% PLGA. 
Formulation OA-3-13 also showed a slow decline in the blood glucose concentrations, 
reaching below 100 mg/dL in 24 hours. 
 
Formulation OA-3-13 also showed a slow decline in the blood glucose 
concentrations, reaching below 100 mg/dL in 24 hours. The blood glucose concentrations 
remained between 100 to 250 mg/dL for 9 days before slowly climbing up to 300 mg/dL 
concentrations at 10 days. The blood glucose concentrations remained above 300 mg/dL 
thereafter. Formulation OA-3-14 (containing 5.6% zinc sulfate) showed a similar pattern 
as that of Formulation OA-3-13. However, the decline in blood glucose concentrations 
was slower (reaching below 100 mg/dL in 2 days) and lasted slightly longer after a 
subcutaneous injection of Formulation OA-3-14 compared to that of Formulation OA-3-
13. Hence, the effect of insulin on the blood glucose concentrations was substantially 
increased with increasing zinc concentrations in the insulin-loaded gel formulations. 
 
Figure 3-8 shows changes in body weights of ZDF rats after subcutaneous 
injections of 5% PLGA gel formulations loaded with 4% insulin and zinc sulfate mixture 
(Formulations OA-3-11, OA-3-12, OA-3-13 and OA-3-14). The changes in body weights 
of the rats repeated the pharmacodynamic trend that had been observed with the change 
in blood glucose concentrations after subcutaneous injections of these formulations. 
 
 
3.4 Conclusions 
 
A biodegradable injectable gel formulation prepared with zinc salts was able to 
sustain the release of insulin for up to 8 to 10 days following a single subcutaneous 
injection. The released insulin from the gel formulations was able to suppress the high 
blood glucose concentrations for the same period of time in the ZDF rats. However, a 
biodegradable injectable gel formulation of human insulin without zinc salts could 
maintain the blood glucose concentrations at low concentrations only for one day. 
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Figure 3-7 Changes in blood glucose concentrations of ZDF rats after subcutaneous 
injections of insulin loaded in PLGA (5%) gel formulations with different concentrations 
of zinc sulfate (2.8% and 5.4%) (Formulations OA-3-13 and OA-3-14) (Mean ± SEM, n 
= 5) 
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Figure 3-8 Changes in body weights of ZDF rats after subcutaneous injections of 
PLGA (5%) gel formulations loaded with 4% insulin and zinc sulfate mixtures 
(Formulations OA-3-11, OA-3-12, OA-3-13 and OA-3-14) (Mean ± SEM, n = 5) 
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CHAPTER 4. CONTROLLED RELEASE OF MODIFIED INSULIN GLARGINE 
FROM NOVEL BIODEGRADABLE INJECTABLE GELS 
 
 
4.1 Introduction 
 
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia, 
which may be due to deficiency or ineffectiveness of metabolic hormone insulin 
produced by Langharan’s beta cells of pancreas. The form of diabetes characterized by 
absolute insulin deficiency is known as type-1. The most prevalent form of diabetes is 
type-2 diabetes mellitus. It accounts for 90% of the cases and is due to ineffectiveness of 
insulin produced by the pancreas (6, 18, 242). 
 
The major objective of diabetes treatment is to achieve normoglycemia by 
maintaining appropriate concentrations of insulin in the blood throughout the day. Insulin 
has been complexed with protamine or zinc to delay and extend the release in vivo and 
prolong its effect for one day. However, these formulations have been associated with 
side effects such as hypoglycemia, and inter and intra-subject variability in absorption, 
and shorter duration of action than expected, thus leading to poor management of 
diabetes (6, 18, 248). 
 
For intensive blood glucose control in people suffering from type-1 and type-2 
diabetes, supply of basal insulin (a steady, low concentration of insulin that is constantly 
present in the circulation to cover post-prandial and overnight fasting periods) is very 
important. Protracted acting insulin preparations supply this basal concentration in 
clinical settings (128, 249, 250). One of the formulations that maintain basal 
concentration insulin is modified insulin called insulin glargine. It has been altered at two 
different positions: in A-chain, at position 21, where the asparagine has been substituted 
with glycine, thus imparting more resistance to deamidation in the acidic environment 
and providing more stability. The C- terminus of the B-chain has been elongated by the 
addition of two arginine molecules. This addition of two positive charges by the addition 
of arginines shifted the isoelectric point of the modified insulin glargine from pH 5.4 to 
6.7. These modifications have made it possible to formulate insulin glargine into slightly 
acid stable solution, which is easy to inject and improves dose reproducibility. This 
insulin glargine solution forms stable hexamers which precipitate at neutral pH at the 
subcutaneous site of injection, thus forming a depot of microprecipitates of the modified 
insulin glargine, which then dissolve at a steady rate for a prolonged period of time (128, 
249, 251). 
 
Insulin and modified insulin like glargine interact with zinc ions to form 
hexamers. In the presence of zinc, these hexamers get further stabilized. When these 
hexamers are injected via subcutaneous route, they form a depot at the site of injection 
because of their inability to cross the capillary barriers. To get absorbed into the blood 
stream, these hexamers have to dissociate first into dimers and then to monomers. This 
leads to a delayed and extended effect of insulin and modified insulin glargine. 
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A novel biodegradable injectable gel system for controlled release drug delivery 
has been designed and characterized in our laboratory. It consists of a biodegradable 
polymer, PLGA, biocompatible plasticizer(s) and an active pharmaceutical ingredient 
(API). To date, several molecules, including antibiotics, opiate analgesics and narcotic 
antagonists, and insulin have been successfully incorporated into the gel system, and 
controlled release of the aforementioned APIs have been achieved in our laboratory. 
 
Therefore, the aim of this study was to develop an injectable biodegradable gel 
system which can be used to control the release of insulin glargine for one week or 
longer, after a single subcutaneous injection in type-2 diabetic ZDF rats. 
 
 
4.2 Materials and methods 
 
4.2.1 Materials 
 
Insulin glargine (Lantus®, Aventis Pharma, Parsippany, NJ) was purchased from 
Cardinal Health and insulin glargine particles were extracted using dialysis bags 
(Spectra/Por® Float-A-Lyzer®, Biotech grade Regenerated Cellulose (RC), 5 mL, 3.5K 
MWCO, Spectrum labs, Rancho Dominguez, CA). Labconco FreeZone® 12 liter Console 
Freeze Dry System (Labconco, Kansas City, MO) was used for freeze drying. 
Recombinant human insulin (insulin) powder (26.9 IU/mg, 0.4% zinc) was purchased 
from Diosynth France S.A. (Usine St. Charles, France). The HPLC analysis of insulin 
was performed on a Shimadzu HPLC system (Shimadzu Scientific Instruments, Inc., 
Columbia, MD). The primary column was a 250 x 4.6 mm Altech Macrosphere RP 300 
C18 5 μm column and the guard column was 7.5 x 4.6 mm (Altech, Deerfield, IL), 
packed with same material as the primary column. HPLC grade Acetonitrile (ACN), 
trifloroacetic acid (TFA) and distilled water were used for preparing the mobile phase. 
The PLGA used in this study was Medisorb® 5050 DL 1A (i.v. 0.09 dL/g) donated by 
Alkermers Inc. (Cambridge, MA). Triethyl citrate (TEC) and acetyltriethyl citrate 
(ATEC) donated by Morflex Inc., (Greensboro, NC) were used as plasticizers. male ZDF 
(fa/fa) rats (Charles River Laboratories, Inc., Wilmington, MA) weighing 300 to 400 
grams were used for the in vivo studies. Blood glucose was measured using Bayer 
Ascensia® Breeze blood glucose meter (Bayer Corporation, Elkhart, IN). The 
concentration of glargine in the plasma or serum was determined using a Mercodia 
human insulin ELISA kit (Mercodia AB, Uppsala, Sweden). Blood glucose and glargine 
monitoring in the animals was stopped when the concentration of blood glucose went 
back to the normally high concentration. 
 
4.2.2 Methods 
 
4.2.2.1 Extraction of insulin glargine particles. The Spectra/Por® Float-A-Lyzer® 
(dialysis bags) were removed from the refrigerator and allowed to equilibrate to room 
temperature. The cap was removed and the sodium azide solution inside the bag was 
discarded using a pipette. The dialysis bags were then cleaned with distilled water and 
placed in a one liter beaker containing 900 mL of distilled water for one hour to remove 
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any remaining sodium azide. The bags were removed from the beaker and again washed 
several times with distilled water. Insulin glargine (Lantus®) solution (5 mL) was loaded 
into each bag using a pipette. The insulin glargine solution filled bags were kept in the 
beaker containing 900 mL of distilled water and the beaker with the dialysis bags was 
placed in an ice bath and stirred continuously with a magnetic stirrer for 24 hours. The 
distilled water in the beaker was completely replaced with fresh water after 2, 4, 8 and 12 
hours. After 24 hours, the cap of the dialysis bag was carefully removed and the sample 
was recovered using a pipette. The recovered sample was placed in a pre-washed 20 mL 
scintillation vial, which was covered with aluminum foil. Holes were punctured in the 
aluminum foil using an 18 gauge needle. This aluminum foil covered scintillation vial 
was then placed in a freezer at -80°C for 6 hours. The freeze dryer was then switched on 
and vacuum was allowed to come to the maximum concentration. The samples were 
removed from -80°C and freeze dried for 12 hours. The dried samples were pooled 
together in a clean 20 mL scintillation vial and sealed with Parafilm, capped and stored at 
-20°C until used for further studies. 
 
4.2.2.2 High pressure liquid chromatography method of insulin glargine. The 
HPLC analysis of the freeze-dried insulin glargine was performed using a Shimadzu 
HPLC system (Shimadzu Scientific Instruments, Inc., Columbia, MD) consisting of an 
SCL-10A vp system controller, a LC-10 AD vp pump, a DGU-14A degasser, an SIL-10 
Ad vp autoinjector with a cooling system, a CTO-10A vp column oven, an SPD-10AD vp 
photo-diode array (PDA) detector and a computer loaded with the Shimadzu Class-VP 
7.2 software. The primary column was a 250 x 4.6 mm Altech Macrosphere RP 300 C18 
5 μm column and the guard column was 7.5 x 4.6 mm, packed with same material as the 
primary column. 
 
A gradient elution method was used for analyzing the insulin. Mobile phase A 
was 0.15% v/v trifluoroacetic acid (TFA) in water and mobile phase B was 0.13% v/v 
TFA in 95% v/v acetonitrile in water. The mobile phases were filtered through a 
Whatmann 0.45 μm nylon membrane (Whatmann International Ltd, Maidstone, England) 
and degassed in an ultrasonicator (Model FS60, Fisher Scientific, Fair Lawn, NJ) for 10 
minutes before pumping it through the HPLC system. 
 
The initial mobile phase composition of 70% solvent A and 30% solvent B was 
maintained at a flow rate of 1 mL/min for 2 minutes. Between 2 and 16 minutes, the 
percentage of solvent B was increased linearly to 50%. These conditions were maintained 
from 5 to 21 minutes. Between 22 and 25 minutes, the percentage of solvent B was 
decreased linearly to 30%. The mobile phase was pumped at a flow rate of 1 mL/min. 
The injection volume of each sample, including the insulin glargine standards, insulin 
glargine controls, insulin glargine samples (unknown concentration) and blank samples 
(0.01N HCl) without insulin glargine), was 50 μL. The temperature of the HPLC column 
was maintained at 30°C by using a column oven. The primary detection wavelength of 
insulin was set to 285 nm. 
 
4.2.2.3 Preparation of standard, control and sample solutions. The standard and 
control solutions of insulin glargine were prepared from the commercially available 
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Lantus® solution with a concentration of 3.63 mg/mL as the working stock solution. 
Standard solutions were prepared from the working stock solution by transferring 50, 75, 
100, 150 and 200 μL of the working stock solution to five 2 mL volumetric flasks and 
making up the volume with 0.01N HCl (pH 2.0). 
 
The insulin glargine controls were also prepared from the working stock solution 
with a concentration of 100 μg/mL. For sample preparations, approximately 5 mg of 
freeze-dried insulin glargine particles were weighed on a calibrated Cahn C-31 
microbalance (Cahn Instruments, Cerritos, CA) and transferred to a volumetric flask and 
dissolved in 0.01N HCl (pH 2.0). The final volume was made with 0.01N HCl (pH 2.0). 
The dissolved samples were immediately loaded on the HPLC tray. 
 
4.2.2.4 Process of chromatographic data. After each HPLC injection, the 
software generated the chromatograph of the sample and integrated the peak area of 
insulin glargine. The peak area of the standard solutions was then plotted against the 
concentration of insulin glargine. A linear regression method was used to generate the 
equation from which the concentration of the unknown sample could be interpolated from 
the peak area. The concentration of the insulin glargine control was interpolated and 
compared to the theoretical value. The concentration of insulin glargine samples was 
determined using the standard curve. 
 
4.2.2.5 Pharmacodynamic studies of insulin and insulin glargine in ZDF rats. All 
the experimental procedures for the animal studies were approved by the University of 
Tennessee Health Science Center’s Animal Resources Advisory Committee. The ZDF 
rats were at least 16 weeks old (weighing 300 to 400 g). Hyperglycemia (> 400 mg/dL) in 
the ZDF rats was confirmed by blood glucose measurements. The rats were group-housed 
(3 per cage) in the animal facility under a 12-hour light/dark cycle. They had access to 
food and water ad libitum throughout the studies. Before the animals were shipped from 
Charles River Laboratories, they were fed Purina diet #5008 until they fully developed 
diabetes (12 weeks old). The animals were on regular laboratory rodent food in our 
facility. The rats were acclimated to the environment for at least three days before they 
were used in the studies. 
 
Insulin (RHI), insulin glargine and the commercially available formulation of 
insulin glargine, Lantus® were administered to the ZDF rats (type 2 diabetes) by a 
subcutaneous injection. An appropriate amount of insulin or insulin glargine powder was 
suspended in sterile normal saline to obtain a suspension with a concentration of 40 
IU/mL (Table 4-1). Lantus® was used as a control and was administered to the animals as 
is (100 IU/mL). 
 
Blood glucose concentrations in each animal were determined following a 
subcutaneous injection of each form of insulin at a dose of 10 IU/kg as follows: On each 
day of the study, the ZDF rats were transferred to the procedure room. The rats were 
randomly divided into groups, with 4 to 6 animals per group. Each group, except the 
control group, received one dose of a form of insulin. The control group did not receive 
any insulin injection. Before injection, each rat was placed in an induction chamber and 
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Table 4-1 Composition of gel formulations used for in vivo studies 
 
 
Formulation 
# 
 
 
Concentration 
of polymer 
*(% w/w) 
 
 
Concentration 
of ATEC 
(% w/w) 
 
Concentration 
of TEC 
(% w/w) 
 
Insulin 
glargine 
(% w/w) 
 
Zinc 
Sulfate 
(% w/w)
 
OA-G-1 
 
- 
 
- 
 
- 
 
4.0 
 
- 
OA-G-2 - 72 24 4.0 - 
OA-G-3 5.0 69.75 23.25 2.0 - 
OA-G-4 5.0 68.25 22.75 4.0 - 
OA-G-5 10.0 64.5 21.5 4.0 - 
OA-G-6 5.0 67.88 22.62 4.0 0.50 
OA-G-7 5.0 67.9 22.9 4.0 0.25 
OA-G-8 
 
5.0 
 
68 
 
22.9 
 
4.0 
 
0.10 
 
 
OA-G-1 was prepared in phosphate buffer saline (PBS) 
* Inherent viscosity of the polymer (dL/g) - 0.09 
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anesthetized by isoflurane (Halocarbon Product Corporation, River Edge, NJ) using a 
SurgiVet/Anesco ventilator (Waukesha, WI). The body weight of the animal was 
recorded to determine the volume of the insulin suspensions to be injected. Blood glucose 
was measured using Bayer Ascensia Breeze blood glucose meter (Bayer Corporation, 
Elkhart, IN). The predetermined dose of insulin (which was determined based on the 
animal body weight) was injected subcutaneously at the dorsal neck of the rat using a ½ 
mL Becton Dickinson Lo-Dose™ U-100 insulin syringe with a permanently attached 28 
gauge x ½ inch needle (Franklin Lakes, NJ). After injection, the rats were returned to the 
cages and allowed to recover from anesthesia. At pre-determined time intervals, the rats 
were anesthetized by the aforementioned method and their blood glucose was measured. 
A plot of blood glucose concentrations versus time was generated from the data to 
describe the glucose lowering effect of insulin or insulin glargine, from which 
information such as time of peak action and duration of action could be obtained. 
 
4.2.2.6 Fabrication of biodegradable gels. The gel formulations (Table 4-1) were 
prepared in two steps: dissolution of polymer in the plasticizer(s) to obtain a blank gel 
and loading of insulin glargine into the blank gel. 
 
The polymer was allowed to come to room temperature in a vacuum desiccator 
after it was taken out from the freezer. Then an appropriate amount of polymer particles 
was accurately weighed into a dry, clean glass scintillation vial using a Mettler AE100 
analytical balance (Mettler-Toledo, Inc., Columbus, OH). The desired amount of 
plasticizer(s) was weighed into the scintillation vial containing the polymer. A plastic 
screw cap with aluminum liner was used to seal the vial. The vial was then vortexed on a 
vortex mixer to disperse the polymer particles in the plasticizer(s). The vial was placed in 
a Lab-Line orbital shaker (Model 3527, Lab-line, Melrose Park, IL), which was 
maintained at 37°C, and shaken at 150 rpm. It took 2 to 3 days for the polymer to 
completely dissolve in the plasticizer. The resulting blank gel was stored in vacuum 
desiccators at room temperature until further use (typically 1 to 2 days). One day before 
the insulin glargine-loaded gel was required, a desired amount of blank gel was 
transferred to a new glass scintillation vial and an appropriate amount (approximately 80 
mg) of insulin glargine particles was accurately weighed and transferred into the blank 
gel vial. A stainless steel spatula was used to disperse the insulin glargine particles 
uniformly into the blank gel. Any visible agglomerates of insulin glargine were broken 
using a spatula and the insulin glargine-loaded gel was ready to be used for the in vivo 
studies. 
 
4.2.2.7 In vivo studies of insulin glargine-loaded gel formulations in ZDF rats. 
For the in vivo studies, blood glucose concentrations of the diabetic rats were measured 
before and after injection of insulin glargine-loaded gels. The concentration of insulin 
glargine of some of the formulations in plasma or serum was also determined and the 
data were plotted against time to characterize the release of insulin glargine from the 
insulin glargine-loaded gel formulations. For gel formulations consisting of insulin 
glargine and zinc sulfate, an appropriate quantity of zinc sulfate powder (< # 400 mesh or 
37.5 µm) was accurately weighed and added to the insulin glargine-loaded gel. 
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Typically, a total of 2 g of gel (including insulin glargine and zinc sulfate) was 
prepared for each gel formulation. On the day of injection, the ZDF rats were transferred 
from the housing room to the procedure room. The animals were anesthetized by 
isoflurane. The dorsal neck of each rat (except the animals in the control group that did 
not receive any injection) was shaved to expose the injection site. Body weight of the rat 
was recorded. Blood glucose was measured prior to any injection using a glucose meter 
as described before. The insulin glargine-loaded gel was withdrawn into a barrel of a 1 
mL syringe, without any needle. Then a 23 gauge needle (1 inch in length) was attached 
to the syringe, and the volume of the gel in the syringe was adjusted to the desired 
volume, depending on the dose of insulin for each animal. The shaved area on the dorsal 
neck of the animal was disinfected with isopropyl swab and a subcutaneous injection of 
the insulin glargine-loaded gel was made. The needle was inserted under the skin in such 
a way that the gel would be injected between the skin and the underlying muscle tissue. 
The actual procedure of injecting the gel was as follows: At the injection site, the skin 
was pinched and lifted by the finger and thumb. The needle was inserted under the skin 
between the finger and thumb. Approximately three-quarters of an inch of needle was 
pierced into the skin to make sure that the injected gel would not ooze out after the needle 
was removed from the injection site. After injection of the gels, at pre-determined time 
intervals, the rats were anesthetized and blood glucose concentrations were measured. 
Blood samples (300 to 400 μL) were taken from the tail vein and processed to collect 
plasma or serum. These plasma or serum samples were stored at -20°C until analysis. 
 
4.2.2.8 Statistical analysis. Area under the effect curve (AUEC) which is defined 
as the area below baseline is representative of the effect of the formulation on lowering of 
blood glucose with greater AUEC implying greater effect. One way ANOVA within 
Excel 2007 was utilized to compare AUEC between treatment (N = 4) and control (N = 
4) at 95% confidence level. 
 
 
4.3 Results and discussion 
 
4.3.1 Purity of insulin glargine particles 
 
Figure 4-1 shows the chromatogram of placebo Lantus® formulation (without any 
insulin glargine). The placebo was made in house and each milliliter of the formulation 
contained 2.7 mg of m-cresol, 30 µg of zinc, (from zinc chloride), 20 mg of glycerol 85% 
w/w and water for injection. This formulation was similar to Lantus® formulation without 
insulin glargine. It is evident from the Figure 4-1 that the retention time of the peak of the 
placebo formulation is approximately 6 minutes. 
 
Figure 4-2 shows the chromatogram of Lantus® formulation diluted in 0.01 N 
HCl. The chromatogram shows two peaks, one at 6 minutes, which corresponds to the 
placebo peak and another peak at 11 minutes. The peak at 11 minutes is the peak of 
insulin glargine or Lantus®. The diluted Lantus® formulations were injected at various 
concentrations and the areas under the peaks at 11 minutes were used to prepare the 
standard plot. 
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Figure 4-1 HPLC chromatogram of placebo of Lantus® formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 78 
 
 
Figure 4-2 HPLC chromatogram of Lantus® formulation 
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Figure 4-3 shows the chromatogram of purified (dialyzed) and freeze-dried 
particles of insulin glargine dissolved in 0.01 N HCl. The chromatogram shows a single 
peak at 11 minutes. It is evident from the Figure 4-3 that the placebo peak at 6 minutes is 
missing, thus indicating that the excipients in the Lantus® formulation were removed 
using the dialysis bags and pure insulin glargine particles were obtained after freeze 
drying. The calculated purity of these insulin glargine particles was found to be 94.6%. 
 
4.3.2 Pharmacodynamic studies of insulin formulations in ZDF rats 
 
Insulin and insulin glargine particles were suspended in sterile normal saline 
(0.9% NaCl) and administered subcutaneously to ZDF rats to evaluate the biological 
effect of different forms of insulin on the blood glucose concentrations of the rats. Figure 
4-4 shows the blood glucose concentrations of these pharmacodynamic studies. It is 
evident from Figure 4-4 that the blood glucose concentrations decreased from 
approximately 452 + 27.38 mg/dL to 92.5 ± 4.9 mg/dL within 3 hours after a 
subcutaneous injection of 10 IU/kg dose of RHI in the ZDF rats. Normal blood glucose 
concentrations (between 80 – 200 mg/dL) were maintained for approximately an hour 
before reaching the normally high blood glucose concentrations within 6 hours. Lantus® 
was subcutaneously injected at dose of 10 IU/kg (Figure 4-4). The blood glucose 
concentrations after Lantus® injection decreased from approximately 441 ± 17.02 mg/dL 
to 229 ± 45 mg/dL within 4 hours post injection. The blood glucose concentrations after 
subcutaneous injection of purified glargine particles suspended in saline decreased from 
approximately 481 ± 16.68 mg/dL to 136.23± 14.56 mg/dL within 2 hours (Figure 4-4). 
 
Normal blood glucose concentrations (between 80 and 200 mg/dL) were 
maintained for approximately 6 hours before reaching the normally high blood glucose 
concentrations (350 mg/dL) within 12 hours. This pharmacodynamic effect of lowering 
of blood glucose concentrations shows that the insulin glargine particles (purified from 
the commercially available Lantus® formulation) and suspended in normal saline were 
bioactive. There was a significant difference between AUEC after subcutaneous injection 
of insulin glargine particles and control at 95% confidence level (P=0.003) indicating that 
insulin glargine particles causes significantly greater reduction in blood glucose when 
compared to control. Moreover, no significant difference was observed between AUEC 
after subcutaneous injection of insulin glargine particles and Lantus® (P>0.05) at 95% 
confidence level indicating that the Lantus® is no better than insulin glargine particles in 
reduction of blood glucose. 
 
4.3.3 In vivo studies of gel formulations loaded with insulin glargine particles 
 
Purified and freeze-dried particles of insulin glargine were suspended in 
phosphate buffer saline (PBS) at 4% loading, and 0.1 mL of this suspension was injected 
subcutaneously in the ZDF rats. Figure 4-5 shows the changes in blood glucose 
concentrations and body weights of ZDF rats after the injection. It is evident from the 
figure that blood glucose concentrations decreased rapidly below 100 mg/dL within 6 
hours after injection and remained at that concentration until day 3 before rapidly 
climbing climbing to above 300 mg/dL on day 5. 
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Figure 4-3 HPLC chromatogram of insulin glargine particles dissolved in HCl 
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Figure 4-4 Blood glucose profiles in ZDF rats after subcutaneous injections of insulin 
(RHI), Lantus® and insulin glargine particles suspended in saline (dose-10 U/Kg) (Mean 
± SEM, n = 5) 
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Figure 4-5 Changes in blood glucose concentrations and body weights of ZDF rats 
after subcutaneous injections of 4% suspension of insulin glargine particles in PBS 
(Mean ± SEM, n = 5) 
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The rapid decline in blood glucose concentrations is not desirable. Moreover, the 
rats were nearly hypoglycemic for three days. Hence, there was a need to further slow 
down the release of insulin glargine, which produced a slower and extended effect in the 
animals. However, from Figure 4-5, it is clear that as the blood glucose concentrations 
decreased, the body weights of the rats increased rapidly. Moreover, the body weights of 
the animals started to decline as the blood glucose concentrations climbed back to the 
normally high concentrations above 350 mg/dL. This showed that the glargine particles 
not only produced a lowering in blood glucose concentrations, but also affected the body 
weights, thus proving that the purified and freeze-dried particles of insulin glargine were 
bioactive. 
 
A similar effect in the change in blood glucose concentrations and body weights 
of ZDF rats was observed after subcutaneous injection of 0.1 mL of 4% suspension of 
insulin glargine particles in 3:1 blend of ATEC: TEC plasticizers (Figure 4-6). Hence, it 
is clear from this study that loading insulin glargine particles in a combination of 
plasticizers alone does not provide extension of biological effect of insulin glargine. 
Figure 4-7 depicts change in blood glucose concentrations and body weights of ZDF rats 
after a subcutaneous injection of PLGA gel formulation (containing 5% PLGA) loaded 
with insulin glargine particles. The drug loading in the gel formulation (Formulation-OA-
G-3) as shown in Table 4-1 was 2% w/w. The drug loading in the gel formulation 
(Formulation-OA-G-3) as shown in Table 4-1 was 2% w/w. The blood glucose 
concentrations reduced from 425 mg/dL to approximately 100 mg/dL within 24 hours 
after the injection and remained between 100 and 200 mg/dL for 4 days before steadily 
climbing back up to above 300 mg/dL on the day 9. This showed that addition of 5% 
PLGA to the plasticizer combination of ATEC:TEC (3:1) not only slowed down the in 
vivo effect of insulin, but also extended the duration of action of the drug for 
approximately 6 days before climbing back up to the normally high concentrations of 
above 350 mg/dL. 
 
Figure 4-8 shows changes in blood glucose concentrations and body weights of 
ZDF rats after subcutaneous injection of gel formulation prepared with 5% PLGA and 
loaded with 4% w/w of insulin glargine particles (Formulation OA-G-4) (Table 4-1). It is 
evident from the figure that the effect of this gel formulation (Formulation OA-G-4) was 
similar to Formulation OA-G-3 with 2% drug loading. The blood glucose concentrations 
dropped from 445 mg/dL to about 100 mg/dL in 24 hours, and remained below 150 
mg/dL for 9 days, before rising steadily above 300 mg/dL on day 13. Hence, doubling the 
drug loading from 2% (Formulation OA-G-3) to 4% (Formulation OA-G-4) extended the 
maintenance of normal blood glucose concentrations from 6 to 9 days, respectively. 
Moreover, the effect of insulin glargine was also seen on the body weights, which 
steadily increased as the blood glucose concentrations dropped. The body weights 
remained high and dropped slightly when the blood glucose concentrations began to rise 
steadily. 
 
To explore the possibility of slower and longer duration of effect of insulin 
glargine in the ZDF rats, the polymer concentration in the gel formulation was increased 
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Figure 4-6 Changes in blood glucose concentrations and body weights of ZDF rats 
after subcutaneous injections of 4% suspension of insulin glargine particles in blends of 
ATEC:TEC (3:1) (Mean ± SEM, n = 5) 
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Figure 4-7 Changes in blood glucose concentrations and body weights of ZDF rats 
after a subcutaneous injection of gel (5% PLGA) formulation loaded with 2% insulin 
glargine particles (Mean ± SEM, n = 5) 
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Figure 4-8 Changes in blood glucose concentrations and body weights of ZDF rats 
after a subcutaneous injection of gel (5% PLGA) formulation loaded with 4% insulin 
glargine particles (Mean ± SEM, n = 5) 
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from 5 to 10% w/w. Figure 4-9 shows changes in blood glucose concentrations and body 
weights of ZDF rats after subcutaneous injection of PLGA gel (prepared with 10% 
PLGA) formulation loaded with 4% insulin glargine particles (Formulation OA-G-5) 
(Table 4-1). 
 
The changes in blood glucose concentrations and body weights of ZDF rats were 
similar to Formulation OA-G-4 containing 5% PLGA gel (Figure 4-8). Hence, increasing 
the PLGA from 5% to 10% did not increase the in vivo duration of activity of insulin in 
the ZDF rats. Figure 4-10 depicts the comparison of blood glucose concentrations in ZDF 
rats after subcutaneous injections of different formulations of insulin glargine with 4% 
loading with (Formulation OA-G-4) or without PLGA (Formulation OA-G-1 & 
Formulation OA-G-2). There was a significant difference between AUEC after 
subcutaneous injection of formulation of insulin glargine with 4% loading with PLGA 
(Formulation OA-G-4) and control at 95% confidence level (P = 0.00001) indicating that 
insulin glargine with 4% loading with PLGA causes significantly greater reduction in 
blood glucose when compared to control. Furthermore, There was a significant difference 
between AUEC after subcutaneous injection of formulation of insulin glargine with 4% 
loading with PLGA (Formulation OA-G-4) and formulation of insulin glargine with 4% 
loading without PLGA (Formulation OA-G-1) at 95% confidence level (P = 0.0004) 
indicating that insulin glargine with 4% loading with PLGA causes significantly greater 
reduction in blood glucose concentrations, when compared to insulin glargine with 4% 
loading without PLGA. 
 
Moreover, no significant difference was observed between AUEC after 
subcutaneous injection formulation of insulin glargine with 4% loading without PLGA i.e 
insulin glargine in PBS (Formulation OA-G-1) and insulin glargine in plasticizers 
(Formulation OA-G-2) (P>0.05) at 95% confidence level indicating that the insulin 
glargine in plasticizers (Formulation OA-G-2) is no better than insulin glargine in PBS 
(Formulation OA-G-1), in reduction of the blood glucose concentrations. It is clear from 
the figure that addition of 5% w/w PLGA not only slows down the lowering of blood 
glucose concentrations, but also increased the duration of action from 3 to 9 days. This 
extension in the blood glucose lowering effect of insulin glargine particles is due to 
presence of PLGA. This effect may be due to formation of a depot of insulin glargine 
particles encapsulated in the PLGA matrix. This PLGA matrix released the insulin slowly 
as it underwent erosion with time. 
 
To study the concentration concentrations of glargine and its effect on blood 
glucose concentrations, Formulations OA-G-1 and OA-G-4 were injected into two 
different groups of 7 ZDF rats. The blood glucose concentrations and concentrations of 
glargine in serum were determined. Figure 4-11 shows the concentrations of glargine in 
serum and blood glucose concentrations after a subcutaneous injection of Formulation 
OA-G-1. The concentration of glargine in serum of the ZDF rats increased very rapidly to 
3563 ± 1228 mIU/L within 6 hours after injection. The concentration of glargine 
remained above 1500 mIU/L until day 3 and then slowly declined below 100 mIU/L 
within 6 days after injection. The blood glucose concentrations dropped to a low 
concentration of 93 ± 31 mg/dL within 6 hours after injection thus corresponding to the 
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Figure 4-9 Changes in blood glucose concentrations and body weights of ZDF rats 
after subcutaneous injections of gel (10%) formulations formulation loaded with 4% 
insulin glargine particles (Mean ± SEM, n = 5) 
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Figure 4-10 Comparison of blood glucose concentrations in ZDF rats after 
subcutaneous injections of insulin glargine (4% loading) in different formulations (Mean 
± SEM, n = 5) 
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Figure 4-11 Blood glucose concentrations and concentrations of insulin glargine in 
serum of ZDF rats after a single subcutaneous injection of Formulation OA-G-1 (Mean ± 
SEM, n = 7) 
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burst release of glargine from the formulation. The blood concentrations remained below 
100 mg/dL for up to 4 days before it gradually went back up. The blood glucose 
concentrations went back up to more than 400 mg/dL on day 6 due to the decline in 
glargine serum concentrations. 
 
Figure 4-12 shows the concentration of glargine in serum of the ZDF rats and 
blood glucose concentrations after a subcutaneous injection of gel Formulation OA-G-4. 
The concentration of glargine in serum of the ZDF rats increased to approximately 750 
mIU/L within 12 hours after injection, and then declined to approximately 500 mIU/L 
within 24 hours after injection. The concentration of glargine was then maintained 
between 260 ± 134.9 mIU/L and 188 ± 55.9 mIU/L until day 10 Glargine concentrations 
decreased to 61.5 ± 16.5 mIU/L on day 11 and then gradually decreased further 
thereafter. The blood glucose concentrations were well correlated to the concentration of 
glargine in the serum. The blood glucose concentrations dropped to a low concentration 
(75 ± 14.5 mg/dL) on the first day after injection and were maintained at the low 
concentration (< 200 mg/dL) for 9 days before it gradually went back up. Blood glucose 
went back up to more than 400 mg/dL on day 13 and then was constantly maintained at 
normally high concentrations as seen before the injection. 
 
Figure 4-13 shows a comparison of serum glargine concentrations in ZDF rats 
after subcutaneous injections of 4% insulin glargine loaded) in PLGA (5%) gel 
formulation (Formulation OA-G-4) and PBS (Formulation OA-G-1). There was a 
significant difference between serum glargine concentrations after subcutaneous injection 
of formulation of insulin glargine with 4% loading with PLGA (Formulation OA-G-4) 
and formulation of insulin glargine with 4% loading without PLGA (Formulation OA-G-
1) at 95% confidence level (P = 0.001) indicating that insulin glargine with 4% loading 
with PLGA causes significantly extension in serum glargine concentrations when 
compared to insulin glargine with 4% loading without PLGA. It is evident from the 
figure that the serum glargine concentrations rose rapidly after subcutaneous injection of 
formulation of insulin glargine with 4% loading without PLGA (Formulation OA-G-1). 
The serum glargine concentrations remained above 500 mIU/L until day 4. The serum 
glargine concentrations decreased to near zero levels on day six. However, the serum 
glargine concentrations rose slowly after subcutaneous injection of formulation of insulin 
glargine with 4% loading with PLGA (Formulation OA-G-4). Furthermore, the serum 
glargine concentrations were above 2500 mIU/L until day 10. 
 
To further study the effect of presence of zinc sulfate in the PLGA gels loaded 
with insulin glargine on the biological effect of these gels, three formulations at different 
concentrations of zinc sulfate were prepared. Figure 4-14 shows the comparison of blood 
glucose concentrations in ZDF rats after subcutaneous injections of different formulations 
loaded with 4% insulin glargine and various zinc sulfate concentrations. It is evident from 
the figure that addition of zinc sulfate in the formulations lowered the rate of blood 
glucose lowering effect. At the highest zinc sulfate concentration of 0.5% (Formulation 
OA-G-6), the blood glucose concentrations never dropped below 300 mg/dL. Moreover, 
the blood glucose concentrations remained between 300 to 400 mg/dL for 14 days. 
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Figure 4-12 Blood glucose concentrations and concentrations of insulin glargine in 
serum of ZDF rats after a single subcutaneous injection of Formulation OA-G-4 (Mean ± 
SEM, n = 6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 93 
0
1000
2000
3000
4000
0 2 4 6 8 10 12 14
Time (days)
 B
lo
od
 g
la
rg
in
e 
co
nc
. (
m
IU
/L
)
Glargine in PLGA (5%) Gel
Glargine in PBS
 
 
Figure 4-13 Comparison of serum glargine concentrations in ZDF rats after 
subcutaneous injections of 4% insulin glargine loaded in PLGA (5%) gel formulation 
(Formulation OA-G-4) and PBS 
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Figure 4-14 Comparison of blood glucose concentrations in ZDF rats after injections 
of insulin glargine (4% loading) in different formulations with various zinc sulfate 
concentrations (Mean ± SEM, n = 5) 
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There was a significant difference between AUEC after subcutaneous injection of 
formulation of insulin glargine with 4% loading with PLGA and zinc sulfate 
concentration of 0.5% (Formulation OA-G-6) and control at 95% confidence level (P = 
0.02) indicating that insulin glargine with 4% loading with PLGA and zinc sulfate 
concentration of 0.5% causes significantly greater reduction in blood glucose when 
compared to control. Furthermore, There was also a significant difference between 
AUEC after subcutaneous injection of formulation of insulin glargine with 4% loading 
with PLGA (Formulation OA-G-4) and formulation of insulin glargine with 4% loading 
with PLGA and zinc sulfate concentration of 0.5% (Formulation OA-G-6) at 95% 
confidence level (P = 0.002) indicating that insulin glargine with 4% loading with PLGA 
causes significantly greater reduction in blood glucose when compared to formulation of 
insulin glargine with 4% loading with PLGA and zinc sulfate concentration of 0.5% 
(Formulation OA-G-6). 
 
As the zinc sulfate concentration was reduced from 0.5% to 0.25% (Formulation 
OA-G-7), the blood glucose concentrations dropped from 520 mg/dL to about 178 mg/dL 
in 2 days, and remained below 200 mg/dL for 8 days, before rising steadily above 400 
mg/dL on day 10. As the zinc sulfate concentration was further reduced from 0.25% to 
0.1% (Formulation OA-G-8), the blood glucose concentrations dropped from 515 mg/dL 
to about 128 mg/dL in 24 hours, and remained below 200 mg/dL for 8 days, before rising 
steadily above 400 mg/dL on day 13. 
 
Moreover, no significant difference was observed between AUEC after 
subcutaneous injection formulation of insulin glargine with 4% loading with PLGA 
(Formulation OA-G-4) and formulation of insulin glargine with 4% loading with PLGA 
and zinc sulfate concentration of 0.25% (Formulation OA-G-7) (P>0.05) and zinc sulfate 
concentration of 0.1% (Formulation OA-G-8) at 95% confidence level indicating that 
formulation of insulin glargine with 4% loading with PLGA (Formulation OA-G-4) is no 
better than formulation of insulin glargine with 4% loading with PLGA and zinc sulfate 
concentration of 0.25% (Formulation OA-G-7) and zinc sulfate concentration of 0.1% 
(Formulation OA-G-8), in reduction of blood glucose concentrations. Hence, zinc sulfate 
could be used as a release modifier for insulin glargine in the gels. However, the amount 
of zinc sulfate in the gel needs to be optimized, so that it can provide a prolonged effect 
in vivo. 
 
 
4.4 Conclusions 
 
Insulin glargine particles were purified and then freeze-dried from commercial 
Lantus® formulation. The purity of the freeze-dried particles of insulin glargine was 
determined using HPLC, and was found to be 94.6%. These insulin glargine particles 
were suspended in saline and subcutaneously injected in ZDF rats. The bioactivity, as 
measured by blood glucose lowering effect, was found to be similar to regular human 
insulin and the marketed formulation called Lantus® The PLGA gel formulations 
prepared with insulin glargine particles had duration of action of 10 days following a 
single subcutaneous injection. The concentration of insulin glargine was maintained 
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between 260 ± 134.9 mIU/L and 188 ± 55.9 mIU/L until day 10 after single subcutaneous 
injection of some of these formulations and he corresponding blood glucose 
concentrations were suppressed from above 400 mg/dL to below 200 mg/dL from day 1 
to day 10 post injection. The addition of zinc sulfate to the formulations prepared with 
purified insulin glargine particles further slowed down the drop in blood glucose 
concentrations. 
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